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ABSTRACT
The first part of this work induced T-cell lymphoma in mice by employing a breeding
scheme involving mouse strains expressing the KrasG12D oncoprotein and mice expressing
cyclic recombinase from the mouse mammary tumor virus promoter. Imprinted domains were
then systematically surveyed for DNA methylation changes during tumor progression using
combined bisulfite restriction analysis and next-generation-bisulfite-sequencing. Hyper-or
hypomethylation was detected at the imprinting control regions (ICRs) of the Dlk1, Peg10, Peg3,
Grb10 and Gnas domains. These DNA methylation changes at ICRs were more prevalent and
consistent than those observed at the promoter regions of well-known tumor suppressors, such as
Mgmt, Fhit and Mlh1. Thus, the changes observed at these imprinted domains are the outcome of
isolated incidents affecting DNA methylation settings. Within imprinted domains, DNA
methylation changes tend to be restricted to ICRs as nearby somatic differentially methylated
regions and promoter regions experience no change. Furthermore, detailed analyses revealed that
small cis-regulatory elements within ICRs tend to be resistant to DNA methylation changes,
suggesting potential protection by unknown trans-factors.
The second part of this work further characterized the epigenetic response of imprinted
domains during carcinogenesis. This study compared the stability of DNA methylation at a
variety of cis-regulatory elements within imprinted domains in two fundamentally different
mouse tumors, benign and malignant. The data suggest that imprinted domains remain quite
stable in benign processes, but are highly susceptible to epigenetic alterations in infiltrative
lesions. The preservation of DNA methylation within imprinted domains in benign tumors
throughout their duration suggests that imprinted genes are not involved with the initiation of
carcinogenesis or the growth of tumors. However, the frequent detection of DNA methylation
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changes at imprinting control regions in infiltrative lesions suggest that imprinted genes are
associated with tumor cells that have gained the ability to defy tissue boundaries.
Overall, this study demonstrates that imprinted domains are targeted for DNA
hypermethylation when benign tumor cells transition to malignant. Thus, monitoring DNA
methylation within imprinted domains may be useful in evaluating the progression of neoplasms.
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CHAPTER 1
INTRODUCTION
1.1 DNA methylation in general
Deoxyribonucleic acid (DNA) was identified in the mid 20th century as a cell’s genetic
material. DNA is a polymer comprised of four nitrogenous bases: adenine (A), guanine (G),
thymine (T) and cytosine (C). Unique combinations of these four bases encode the genetic
information for all of the various life forms on earth. These unique combinations or “genomes”
are faithfully passed to subsequent generations either by asexual or sexual reproduction, and thus
patterns of inheritance emerge. The field of genetics has been dedicated to understanding DNA
sequence and how sequence variation influences heritable differences in gene expression.
However, geneticists have observed that not all patterns of inheritance can be explained by
variations in genome sequences alone. In fact, there exist layers of heritable information in
addition to genomic sequence variations that have profound influences on gene expression. Enter
the field of epigenetics. In this section, a principle component of epigenetics, termed DNA
methylation, is discussed in the context of the mammalian genome. It should be noted, however,
that DNA methylation is a central epigenetic mechanism in other genomes including plants,
fungi, insects, and even bacteria [1,2,3].
DNA methylation is a layer of epigenetic information deposited directly onto nucleic acid
content. Since it’s discovery, DNA methylation has been shown to be critical for regulating gene
expression and cell fate decisions [4]. As such, improper regulation of DNA methylation has
been linked to numerous human disorders and cancers [4,5]. In these cases, either excessive
DNA methylation (i.e., hypermethylation) or deficient DNA methylation (i.e., hypomethylation)
contributes to the onset of abnormal gene expression. However, these abnormal DNA
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methylation settings often accompany each other as seen in human cancer. Therefore, many
recent efforts have focused on not only understanding the contributions of DNA methylation to
normal and abnormal cell function, but also how DNA methylation can either serve as an
epigenetic biomarker or be targeted for therapeutic interventions [6]. These efforts are discussed
in further detail below.
The most common form of DNA methylation in mammals is 5-methylcytosine (5mC), which
is the product resulting from the covalent addition of a methyl substituent to the 5th position of a
cytosine ring (Figure 1.1) [4]. The methyl groups are deposited symmetrically onto both strands
of the DNA double helix most often in cytosine-phosphate-guanine (CpG) palindromic
sequences [4]. Occupancy of this position on cytosine residues at CpG sites spatially orients the
methyl groups so that they protrude into the major grove of the DNA double helix (Figure 1.1)
[7]. Thus far, there are two well-supported models that depict the function of this spatial
orientation. First, the methyl groups cause steric hindrance, and thus block proteins from
associating with DNA sequences containing methylated CpG sites [1]. Conversely, the methyl
groups can serve as a docking site for certain proteins [1]. In either case, DNA methylation
mostly functions to repress gene expression by blocking the binding of transcription factors to
the DNA or by recruiting histone-modifying complexes that facilitate heterochromatin
formation. However, in rare cases such as at the FoxA2 promoter, DNA methylation can also
activate gene expression by inhibiting the association of transcriptional repressors with the DNA
such as the Polycomb group proteins [8]. Nevertheless, DNA methylation acts to physically
block proteins from interacting with DNA with the exception of proteins that have a methylCpG-binding domain (MBD) such as methyl CpG binding protein 2 (MeCP2) [9,10].
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Figure 1.1. DNA methylation on cytosine residues generates 5-methylcytosine. (A) Molecular
structure of cytosine and 5-methylcytosine. DNA methyltransferase enzymes catalyze the
covalent addition of methyl substituents onto cytosine residues to generate 5-methylcytosine. (B)
Methyl substituents on 5-methylcytosine protrude into the major groove DNA double helix. Gold
stars represent methyl substituents.
In a broader view, DNA methylation is dispersed in varying degrees throughout major
locations in the genome and has different regulatory implications depending on the underlying
sequence on which it is deposited. DNA methylation is relevant to three major locations in the
genome. First, CpG islands are regions of the genome that are enriched with CpG sites (i.e.,
genomic sequences at least 300bp long with greater that 50% GC content) and often co-localize
with gene promoters [11]. CpG islands are typically void of DNA methylation with the exception
of specific cases such as gene promoters that need to be silenced in certain cell types or when
CpG islands are imprinted as differentially methylated regions (DMR) [4,11]. The absence of
DNA methylation at CpG islands is permissive to gene expression [11]. However, the
unmethylated profile of CpG islands can make them a target for local DNA hypermethylation
events, and thus gene repression during carcinogenesis [12]. Second, intergenic regions are
regions of the genome that are located between genes. Transposable elements, which make up
conservatively 45% of the genome, are the main sequence elements found within intergenic
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regions [13]. DNA methylation is abundant at mobile elements and is critical to inhibit their
replication and subsequent insertion into new places of the genome, which can result in gene
disruption and genomic instability [14]. Lastly, gene bodies are regions of the genome that
contain the exons and introns of genes. However, the first exon is an exception as DNA
methylation within this exon is also repressive to gene expression just as in promoter regions [4].
The function of DNA methylation within genes bodies is still unclear; however, it is
hypothesized to be involved with regulating transcriptional splicing [15,16]. Also, there is
competing evidence as to whether DNA methylation in gene bodies is associated with increased
gene transcription depending on the mitotic state of cells [4]. In any case, DNA methylation is
intricately tied to management of gene transcripts.
DNA methyltransferase (Dnmt) enzymes are responsible for generating 5mC by catalyzing
the transfer of a methyl substituent from S-adenyl methionine to cytosine residues (Figure 1.1)
[17]. Dnmt enzymes are capable of adding the methyl group to completely unmethylated, native
DNA (i.e., de novo DNA methylation) or to newly replicated, hemimethylated DNA (i.e.,
maintenance DNA methylation). The enzymes mainly responsible for de novo methylation are
Dnmt3a and Dnmt3b, while Dnmt1 preferentially targets hemimethylated DNA to maintain
DNA methylation patterns [18,19]. Dnmt3L is the fourth member of the Dnmt family of
enzymes; however, Dnmt3L lacks the catalytic domain required for DNA methylation. Dnmt3L
does, however, facilitate de novo DNA methylation by stimulating the catalytic activity of both
Dnmt3a and Dnmt3b [20,21,22,23]. While Dnmt3a and Dnmt3b have been shown to be critical
in targeting de novo methylation to sequence elements such as specific DMRs and transposable
elements during development, Dnmt3L has been implicated in de novo methylation of a broader
range of sequence elements due to its association with both Dnmt3a and Dnmt3b. While it is
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understood that maintenance DNA methylation is stimulated by replication, it is less clear how
cells target de novo methylation to specific regions of the genome. The current working
hypotheses regarding factors that can influence de novo DNA methylation include: RNA
interference (RNAi) mechanisms, recruitment by transcription factors, occupancy of DNA by
transcription factors, and crosstalk with histone modifications [24,25,26,27,28,29]. Overall, the
ability of cells to perform maintenance and de novo DNA methylation is critical for proper cell
function and development; however, improper regulation of these pathways can have profound
effects that can contribute to disease states.
DNA methylation is not only written but also erased. There are two main models for DNA
demethylation, passive and active demethylation. First, passive DNA demethylation does not
require enzymatic activity. In this case, DNA methylation is diluted after successive rounds of
cell division without activity of Dnmt1 and the accompanying maintenance DNA methylation of
hemimethylated DNA produced during replication [30]. This pathway of demethylation is
implicated in developing cells and quickly dividing tumor cells that either house a loss-offunction mutation in the Dnmt1 gene or an epigenetic mutation that silences expression of the
Dnmt1 gene [1]. Furthermore, passive demethylation has been exploited as a therapeutic option
in cancer [31]. This therapeutic approach is further discussed below. Second, active DNA
demethylation requires the enzymatic activity of either the ten eleven translocation (TET) family
of proteins or the activation-induced cytidine deaminase/apo-lipoprotein B mRNA-editing
enzyme complex (AID/APOBEC). In this case of the TET enzymatic pathway, DNA
methylation is lost due to the direct modification of the methyl group on cytosine residues, which
generates successive oxidized intermediates. The final oxidized form is then recognized by the
base excision repair (BER) pathway, which replaces the oxidized form of 5mC with a naked
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cytosine [32]. The activity of the TET enzymes and the resulting oxidized versions of 5mC are
also implicated in cancer, which is further discussed below [33]. In the case of the
AID/APOBEC pathway, the amino group is targeted for deamination. This effectively converts
5mC to thymine, which is then improperly base paired with guanine. This T-G base pair
mismatch also triggers the BER pathway [4]. Overall, the ability of cells to remove DNA
methylation is critical for their normal function, but also has implications in disease states.
DNA methylation is not a standalone epigenetic mechanism. In fact, DNA methylation acts
in concert with other epigenetic mechanisms such as histone modification. In this case, DNA
methylation can influence the histone code, and vice versa histone modifications can influence
the activity of the Dnmt enzymes. First, as mentioned earlier, DNA methylation can serve as a
docking site for MeCP2 [9,10]. Once bound to methylated DNA, MeCP2 can then recruit two
classes of histone modifying complexes: histone methyltransferases that catalyze methylation of
histone 3 lysine 9, and histone deacetylases that are responsible for removing acetyl moieties
from lysine residues in histone tails [4]. Both of these changes to the local histone environment
are repressive to gene expression, and thus are considered to reinforce the repressive nature of
DNA methylation to gene expression. Second, histone modifications can directly influence the
establishment of DNA methylation. In this case, certain histone marks can either facilitate or
antagonize the establishment of DNA methylation. For example, while histone 3 lysine 27
trimethylation can recruit the binding of Dnmt3a and stimulate its methytransferase activity,
histone 3 lysine 4 trimethylation prevents DNA methylation by impairing the binding of all three
Dnmt enzymes to histone 3 tails [34,35]. Overall, it is now clear that DNA methylation and
histone modifications can not only influence the establishment of one another, but these layers of
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epigenetic information can support one another in regulating gene expression and ensuring
inheritance of epigenetic information.

1.2 DNA methylation in genomic imprinting
Genomic imprinting is well known example of heritable differences in gene expression that
is independent of genomic sequence variation. This concept was elegantly demonstrated in the
early 1980s by experimentally transplanting murine pronuclear material to generate maternal and
paternal uniparental embryos, none of which survived [36]. These assays allowed the researchers
to conclude that the developing embryo requires both paternal and maternal contributions to its
genome because each parental allele must express a different subset of genes. Subsequent
experiments have identified specific genes that are expressed strictly from a single allele
dependent upon whether the allele is paternally or maternally inherited [37,38,39,40,]. Further
investigations lead to detecting differential DNA methylation between the paternal and maternal
chromosomes, and that DNA methylation functions to repress transcription of imprinted genes
from the allele on which it is deposited [12,36,41]. Thus, imprinted genes are referred to as either
a paternally expressed gene or a maternally expressed gene. Thus far, at least 100 imprinted
genes have been identified and mapped in the murine genome [36].
Imprinted genes tend to be clustered into distinct chromosomal domains that exhibit unique
regulatory features including complex DNA methylation patterns, non-coding RNA, and
enhancers [41]. First, imprinted domains contain cis-regulatory sequence elements termed DMRs
that are differentially methylated in a parent-of-origin dependent manner. DNA methylation is
deposited at DMRs either during gamete production or somatic cell differentiation, and thus a
DMR is classified as either a gametic DMR or a somatic DMR, respectively [36,41]. The

7

fundamental difference between gametic and somatic DMRs is that the DNA methylation status
at a gametic DMR can influence the expression of several imprinted genes in the domain, while
DNA methylation at a somatic DMRs only influences expression of the imprinted gene that it is
associated with. Therefore, gametic DMRs are designated imprinting control regions (ICRs)
[36,41,42]. DNA methylation at DMRs functions as an epigenetic repressor within imprinted
domains as imprinted gene promoters are often embedded within the DMR, and thus the
respective imprinted gene is only expressed from the allele without DNA methylation. Second,
imprinted domains feature long non-coding RNA (lncRNA) genes [41]. These lncRNA genes are
also imprinted due to the DNA methylation settings within their respective domain and their
promoter often being embedded within the domain’s ICR. Experimental truncation of Airn in the
Igf2r domain and Kcnq1ot1 in the Kcnq1 domain revealed that these lncRNA genes function to
regulate the mono-allelic expression of nearby protein coding genes whose promoters are not
differentially methylated [43]. This demonstrates that DNA methylation can indirectly control
the imprinting of genes in which it is not directly associated. Third, imprinted domains feature
distal regulatory sequence elements termed enhancers. These sequence elements have been
implicated to be involved with the spatial and temporal expression of imprinted as well as their
proper mono-allelic expression [44,45]. As discussed in more detail below, DNA methylation at
ICRs has a role in directing enhancers in the domains to associate with certain promoters [36,41].
The role of DNA methylation at the enhancer themselves however is still unclear; however, the
transient nature of DNA methylation at enhancers may dictate when and in which tissues
enhancers may associate with imprinted gene promoters in the domain [44]. Overall, imprinted
domains are regulated by several epigenetic mechanisms acting in concert, with DNA
methylation at ICRs being the central component that orchestrates the regulations.
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As alluded to above, genomic imprinting is established by an intricate interplay among
several epigenetic mechanisms. To date, three models of genomic imprinting have been
proposed, all of which depend on parent-of-origin DNA methylation patterns at ICRs (Figure
1.2) [46]. First, the insulator model is demonstrated at the H19/Igf2 locus [47]. In this case, DNA
methylation deposited on the paternal allele at the H19 ICR inhibits the binding of the CCCTC
binding factor (CTCF). Thus, CTCF is only allowed to bind the maternal allele. The docking of
CTCF on the maternal allele prevents (insulates) downstream enhancers from interacting with
the Igf2 promoter, and thus the enhancer element associates only with the H19 promoter on the
maternal allele to stimulate expression. Due to the lack of interaction, DNA methylation is then
deposited on the maternal allele at the Igf2 promoter/DMR ensuring transcriptional silencing.
Oppositely, the DNA methylation imprint on the paternal allele spreads into the H19 promoter to
ensure transcriptional silencing. The absence of CTCF occupancy on the paternal allele allows
the downstream enhancers to associate with the Igf2 promoter to stimulate transcription.
Second, the lncRNA model is demonstrated at the Igf2r locus [48]. In this case, DNA
methylation at the ICR on the maternal allele silences transcription of the Airn lncRNA, which
allows for Igf2r, Slc22a2 and Slc22a3 to be transcribed from the maternal allele. However, the
lack of DNA methylation at the ICR on the paternal allele allows the Airn lncRNA to be
transcribed. The Airn lncRNA then represses transcription of Slc22a2 and Slc22a3 by
accumulating at the promoters of these genes on the paternal allele, which recruits the G9a
protein to establish repressive histone marks [49]. The Airn promoter is antisense to Igf2r, and
thus transcription of the Airn silences Igf2r expression from the paternal allele.
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Figure 1.2. Models of genomic imprinting. Empty lollipops represent unmethylated CpG islands.
Filled in lollipops represent methylated CpG islands. Black bars represent genes. Pink arrows
represent maternally expressed genes. Blue arrows represent paternally expressed genes. Red
strikethrough signs represent silenced gene expression. Purple bars represent enhancer elements.
T-bars represent inhibition. (A) Insulator model. (B) Long non coding RNA model. (C) Enhancer
competition model.
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Third, the enhancer competition model is demonstrated at the Peg3 locus [50]. In this case,
the DNA methylation status at the ICR determines whether an upstream enhancer will interact
with the bidirectional promoter for Peg3 and Usp29 or with Zim1 promoter. When the ICR is
unmethylated on the paternal allele, the bidirectional Peg3 and Usp29 promoter outcompetes the
Zim1 promoter to associate with the upstream enhancer. However, DNA methylation at the ICR
on the maternal allele inhibits the bidirectional Peg3 and Usp29 promoter from interacting with
the enhancer, and thus the enhancer is now free to interact with the Zim1 promoter. Overall,
DNA methylation at ICRs is central to controlling the parent-of-origin expression of several
genes within an imprinted domain.
DNA methylation at ICRs must be erased and rewritten to ensure the proper parent-of-origin
expression profiles in offspring. This epigenetic reprogramming happens during gametogenesis
in the parents; however, there are slight differences between spermatogenesis and oogenesis.
First, the epigenetic reprogramming occurs at different developmental stages of male and female
gametogenesis. While imprints are erased in both male and female primordial germ cell lineages,
the male germ line undergoes prenatal de novo DNA methylation at ICRs whereas the female
germ line undergoes postnatal de novo DNA methylation at ICRs during oocyte maturation [41].
The functional role for this difference in activity of de novo DNA methylation in each germ line
is still unclear. Second, different sets of genes are imprinted in the two germ lines. Although it is
not fully understood how each germ line targets each set of genes for imprinting, recent reports
have shed some light on this mystery in the developing oocyte. This series of experiments
discovered a link between transcription originating from upstream alternative promoters to ICRs
and activity of de novo DNA methylation at ICRs in the oocyte [51,52]. However, it is still
unknown whether developing spermatocytes employ this same mechanism to target de novo
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DNA methylation at ICRs as paternally methylated ICRs tend to be within intergenic regions.
Nevertheless, developing spermatocytes and oocytes have to globally reset DNA methylation
and subsequently rewrite DNA methylation at specific imprinted loci to establish paternal and
maternal imprints, respectively. Overall, this epigenetic cycling implies mechanisms are in place
within imprinted domains that can recruit both de novo DNA methylation machinery as well as
DNA demethylation machinery to ICRs.

1.3 DNA methylation in cancer
The onset of cancer has classically been attributed to genomic mutations that critically
change gene functions. Irreversible sequence changes that impact gene function undoubtedly
drive carcinogenesis [4]. However, it is now well accepted that improper regulation of epigenetic
information can coordinate with genomic mutations to increase tumor heterogeneity to promote
clonal expansion [53]. As a stable and strong epigenetic repressive signal, DNA methylation has
gained considerable attention as a major factor that contributes to critical changes in gene
expression to promote carcinogenesis. Indeed, DNA methylation in tumor cells is improperly
regulated as both hypermethylation and hypomethylation is observed in a single primary tumor
[54]. While DNA hypomethylation patterns are more widespread throughout the genome, DNA
hypermethylation tends to be more focal in nature occurring at regions that are functionally
relevant to promote a given tumor type [12,55]. Thus, different patterns of hypo-and
hypermethylation are selected for and fixed in different populations of tumor cells. Unique
patterns of methylation have also been correlated with different stages of progression of a single
primary tumor [54]. Somatic evolution of tumor cells drives this selection process, which
effectively generates unique heritable molecular signatures among the various forms and stages
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of cancer. These molecular signatures combined with the ease at which DNA methylation
changes can be detected, make DNA methylation an ideal candidate as a biomarker to enhance
cancer prognosis. Furthermore, the plasticity of DNA methylation makes it a prime target for
therapeutic interventions.
DNA hypermethylation mainly functions to suppress gene expression in tumor cells [12,55].
As mentioned above, DNA hypermethylation in tumor cells occurs in a rather focal manner. It is
not yet understood how focal DNA hypermethylation patterns arise. First, certain regulatory
sequence elements may be specifically targeted for DNA hypermethylation. Conversely, DNA
hypermethylation may occur in a random fashion and only certain hypermethylation events that
confer a competitive advantage for a given tumor cell over adjacent normal cells are selected for
and fixed by clonal expansion. Nonetheless, focal DNA hypermethylation has been reported
most often at CpG islands containing promoters of tumor suppressor genes; however, frequent
hypermethylation of enhancer elements has recently been reported [56]. In either case, DNA
hypermethylation can negatively impact gene dosage. Overall, DNA hypermethylation during
carcinogenesis has been reported to inactivate genes involved in the following cellular processes:
cell-cycle, apoptosis, angiogenesis, DNA damage repair, cell differentiation, transcription, and
signal transduction [4,12,55].
DNA hypomethylation may contribute to carcinogenesis in a variety of ways. While DNA
hypermethylation is clearly demonstrated to be locus-specific, DNA hypomethylation tends to
occur throughout the genome mostly at repeated sequences, which can have several implications.
For example, transposable elements are frequently hypomethylated during carcinogenesis [4,57].
Transposable elements are a main class of repeat sequences that have the unique ability to move
around the genome by either cut and paste or a copy and paste mechanisms [58]. DNA
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methylation at transposable elements inhibits their ability to move around in the genome, and
thus losing DNA methylation at these repeat elements can release their ability to transpose.
When a transposable element inserts into a new location it can disrupt gene activity. Thus,
hypomethylation at transposable elements can increase mutation rates in a tumor cell, which in
turn can increase the rate at which of the tumor cell progresses toward malignancy [59].
Centromeric regions are another example of repetitive sequences that are frequently
hypomethylated. In this case, loss of DNA methylation decreases centromere stability leading to
increased chromosomal rearrangement within centromeric regions [4,57]. In either case, genomic
instability is increased with DNA hypomethylation, which in turn leads to higher mutation rates
and acceleration through carcinogenesis.
ICRs contain sequence elements that make them attractive targets to aberrant DNA
methylation during carcinogenesis [60]. First, ICRs contain at least one CpG island, which
makes them targets for DNA hypermethylation. Second, ICRs contain tandem repeat sequences,
which makes them targets for DNA hypomethylation. In either case, aberrant DNA methylation
at ICRs can potentially impact the proper regulation of imprinting within the domain. For
example, DNA hypermethylation at the ICR within the H19/Igf2 domain in colorectal cancer
correlated with loss of imprinting for Igf2 by allowing the upstream enhancer to associate with
the Igf2 promoter on both alleles [61]. This report demonstrated that ICRs are primed for the
Knudson two hit hypothesis, which posits that the accumulation of mutations are required for the
onset of cancer [62]. For imprinted genes, genomic imprinting on one allele provides the first
“hit” and subsequent aberrant DNA hypermethylation on the other allele can serve as the second
“hit” to relieve genomic imprinting within the domain. Oppositely, DNA hypomethylation of the
imprinted allele can also relieve genomic imprinting and for example result in bi-allelic
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expression of imprinted genes with oncogenic potential. Overall, only one allele within imprinted
domains needs to be targeted for either hyper-or hypomethylation to fulfill the Knudson two hit
hypothesis and promote carcinogenesis.

1.4 Statement of research objectives
DNA methylation has been extensively studied in the last few decades. These studies have
demonstrated that DNA methylation is a central epigenetic mechanism regulating gene
expression especially in the context of genomic imprinting, which in its own merit is a complex
heritable gene dosage mechanism. Abnormal DNA methylation is an epigenetic mutation
frequently detected in a variety of mammalian tumors. In this study, the epigenetic stability of
imprinted domains is hypothesized to be particularly susceptible during carcinogenesis because
DNA methylation changes at ICRs need to occur at only one allele to effectively relieve genomic
imprinting within the domain, potentially resulting in the simultaneous increased expression of
imprinted genes with oncogenic potential and decreased expression of imprinted genes with
tumor suppressor activity. Thus, the Knudson “two hit” hypothesis is satisfied with only a single
epigenetic “hit” to an ICR. The hypothesis of this study is further supported by the notion that
progression through carcinogenesis is a Darwinian selection process of cells that gain a
reproductive advantage over their normal cell counterparts by accumulating both genetic and
epigenetic mutations that promote cell division.
Abnormal DNA methylation within imprinted domains is not a stranger to cancer. However,
the epigenetic stability of imprinted domains throughout carcinogenesis is not fully understood.
First, it is largely unknown when DNA methylation settings go awry within imprinted domains
during carcinogenesis. Second, it is unclear which regulatory sequence elements within
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imprinted domains experience significant DNA methylation changes: are epigenetic changes in
imprinted domains equally distributed or are certain regulatory sequence elements targeted? This
study sought to address these questions by characterizing the epigenetic response of imprinted
domains by profiling DNA methylation changes during carcinogenesis driven by an oncogenic
mutation. A better understanding of when DNA methylation settings are altered within imprinted
domains during carcinogenesis will increase our understanding of how improper regulation of
imprinted genes contributes to carcinogenesis. Furthermore, the results from this study may be
adapted to clinical settings as epigenetic biomarkers during prognosis.
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CHAPTER 2
EPIGENETIC INSTABILITY AT IMPRINTING CONTROL REGIONS
IN A KRASG12D-INDUCED T-CELL NEOPLASM1
2.1 Introduction
DNA methylation at ICRs ensures proper dosage of imprinted genes by restricting their
expression from only one allele based upon parental origin [1]. This strict gene dosage control
makes sense given the fact that imprinted genes have critical roles in controlling fetal growth
rates, brain functions and energy regulations [1,2]. The biochemical functions of many
imprinted gene products are also in accordance with these roles, as they tend to be clustered in
signaling pathways responsible for either cell growth or death [3,4,5]. Consequently,
perturbations to the epigenetic modifications that regulate imprinted gene dosage have been
implicated as factors contributing to neoplastic transformation of tumor cells [6,7]. Among the
approximate 100 imprinted genes identified thus far, the following genes are frequently
associated with cancer: Igf2 (Insulin-Like Growth Factor 2), Igf2r (Igf2 Receptor), Gnas
(stimulatory GTPase alpha), Dlk1 (Delta-Like 1 Homolog), Peg10 (Paternally Expressed Gene
10), Peg3 (Paternally Expressed Gene 3), Plagl1/Zac1 (Pleiomorphic Adenoma Gene-Like 1),
Grb10 (Growth Factor Receptor-Bound Protein 10), Ube3A (Ubiquitin Protein Ligase E3A) and
Mest (Mesoderm-Specific Transcript) [8].
Imprinting Control Regions are the key cis-regulatory elements that dictate the allele-specific
expression patterns for entire imprinted domains [1]. ICRs and their associated allele-specific
DNA methylation patterns are critical for establishing and maintaining genomic imprinting [9].
When an ICR is hyper-or hypomethylated it cannot properly control expression of the multiple
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mRNAs in the domain by either activating ncRNA in cis or interacting with proteins that insulate
promoters from distal enhancer elements [10]. Given the role DNA methylation plays in the
proper function of ICRs, it is reasonable to predict that aberrant DNA methylation of ICRs could
disrupt the imprinting of entire domains, which could then contribute to malignant
transformation. Indeed, both DNA methylation and genomic imprinting are challenged in cancer
[11,12]. Therefore, within imprinted domains, ICRs may be particularly vulnerable to aberrant
DNA methylation during tumor progression. However, the timing and prevalence of DNA
methylation changes at ICRs have not been systematically investigated in the context of
carcinogenesis.
To test if ICRs are particularly susceptible to epigenetic insult during carcinogenesis, we first
induced lymphoblastic T-cell thymic lymphoma in mice using the KrasG12D mutation under
control of the Cre/LoxP system, and then systematically characterized DNA methylation changes
within imprinted domains during the progression of the disease from an early stage
(hyperplastic) to a late stage (neoplastic). According to the results, DNA methylation changes
tend to be restricted to certain regulatory elements within imprinted domains and accumulate
progressively among the imprinted domains as the disease advances toward more infiltrative
states. NGS-based bisulfite sequencing also revealed that certain CpG sites tend to avoid DNA
methylation changes within ICRs that show overall change. In sum, this study demonstrates that
DNA methylation changes are frequent and dynamic at ICRs during lymphoblastic T-cell thymic
lymphoma carcinogenesis.
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2.2 Results
Oncogenic KrasG12D expression results in an infiltrative T-cell neoplasm. In this study, we
challenged a subset of murine cells in vivo with the KrasG12D mutation and concomitant
abrogation of PEG3 protein seeking to test Peg3 as a tumor suppressor. To accomplish this, we
employed two floxed alleles: LSL-KrasG12D and Peg3floxed (Figure 2.1). First, the LSL-KrasG12D
allele features a floxed set of polyA termination signals inserted between the 1st and 2nd exons of
the Kras locus. The 2nd exon is modified with a point mutation causing a substitution (glycine to
aspartic acid) for the 12th amino acid of the KRAS protein [13,14]. The termination cassette
prevents transcription of the oncogenic KrasG12D form until it is removed by the activity of cyclic
recombinase (Cre) (Figure 2.1). Second, the Peg3floxed allele features the 6th exon flanked by two
loxP sites and thus is excised upon Cre-mediated recombination [15,16]. The PEG3 protein
cannot be translated from the modified ORF of Peg3del6 due to a frame shift and subsequent
nonsense mutation. Therefore, when the recombined allele (Peg3del6) is paternally transmitted,
the result is the abrogation of PEG3 protein due to the introduced mutation on the paternal allele
and the silencing of the maternal allele by genomic imprinting (Figure 2.1).
To target these mutations to various tissues/cell types in mice, we employed an allele,
MMTV-Cre, which drives expression of Cre by the Mouse Mammary Tumor Virus (MMTV)
long terminal repeat promoter (Figure 2.1) [17]. This allele has been shown to express Cre in
many of the same cell types where Kras and Peg3 are both expressed [18]. The employed
breeding scheme yielded four cohorts (Figure 2.1). The two experimental cohorts were LSLKrasG12D; Peg3floxed; MMTV-Cre (KPM) and LSL-KrasG12D; MMTV-Cre (KM), whereas the two
negative control cohorts were Peg3floxed; MMTV-Cre (PM) and MMTV-Cre (M). In cells
expressing MMTV-Cre, the proteins produced for each cohort are as follows: KPM (KRASG12D
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and Cre), KM (KRASG12D, PEG3 and Cre), PM (Cre), and M (PEG3 and Cre). Specific PCR
genotyping of thymic DNA confirmed expected recombinant products for each cohort (Figure
2.1).
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Figure 2.1. Targeting oncogenic KrasG12D expression and PEG3 deletion to the mouse thymus.
(A) Upon Cre-mediated recombination: the allele housing the KrasG12D mutation (denoted by
*12D) is conditionally expressed by removal of a tandem polyA signal. The critical exon six
(denoted by yellow coloration) of Peg3 is conditionally deleted. Blue font denotes the allele is
paternally inherited and pink font denotes the allele is maternally inherited. Grey boxed denote
exons. Black triangles denote loxP sites. Filled in lollipops denote a methylated CpG island.
Empty lollipops denote an unmethylated CpG island. (B) Breeding schematic from mating LSLKras+/G12D; Peg3+/del6 mice with MMTV-Cre mice to generate KPM, KM, PM, and M cohorts.
(C) Specific PCR analysis of genomic DNA isolated from thymus confirms recombinant
products for each of the targeted alleles.
We obtained 17 litters from the breeding scheme described above, which yielded a total of 91
mice consisting of 12 KPM, 26 KM, 10 PM, and 43 M (Figure 2.2). In general, there were no
obvious differences in the gross physical appearance of individuals for each cohort at birth;
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however, by one month of age, the coat for both KPM and KM mice appeared glossy and thin.
This phenotype is thought to be the result of sebaceous gland hyperplasia (Figure 2.3). After one
month of age, both KPM and KM mice started developing squamous papillomas on their mucus

A

C

Liver
Liver

% Survival

M"(n=45);"PM"(n=10)"

KM"(n=26)"
KPM"(n=12)"

Age (days)

Mean % weight

Thymus
Spleen
Thymus
Spleen

B

Kidney

Spleen

Liver

Figure 2.2. Gross features of mice expressing the KrasG12D mutation. (A) Kaplan-Meier
comparative survival analysis of KM, KPM, PM and M cohorts. Median survival of KPM and
KM mice was significantly less than PM and M cohorts (p < 0.001, log-rank test, for each
pairwise combination). (B) Organ weight profiles of KPM, KM, PM and M cohorts. Spleen and
liver percent of body weight was significantly increased in KPM and KM cohorts (p < 0.001,
pairwise T-test). (C) Images of hepatomegaly, enlarged thymus, and splenomegaly.
membranes, both oral and perianal (Figure 2.3). This is consistent with observations from
previous studies of LSL-KrasG12D mice [19]. The squamous papillomas caused discomfort for the
animals such that they experienced difficulties eating and defecating to a point that the animals
of the KPM and KM cohorts often experienced significant weight loss (15% of body weight) by
two-to-four months of age. Furthermore, within this time period, we observed that mice in both
the KPM and KM cohorts started to experience labored breathing, lethargy, and signs of pain.
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Based on these observations, it was deemed necessary to euthanize animals showing signs of
distress or significant weight loss. As a result, the survival of experimental cohorts (KPM and
KM) was significantly reduced (p < 0.001) compared to that of the negative control cohorts (PM
Spleen

Liver

Skin
A

C

E

B

D

F

M

KM

Figure 2.3. Histological features of mice expressing the KrasG12D mutation. (A-F)
Representative histopathology of skin, liver and spleen (magnifications in parentheses), H&E
staining. (A) Facial skin of a MMTV-Cre (M) control mouse (100X) shows the normal thickness
of the epithelial layer and the normal number of sebaceous glands/hair follicles (arrows). (B)
Perianal skin of an L-KrasG12D;MMTV-Cre (KM) experimental mouse (40X) shows a squamous
papilloma characterized by multiple finger-like projections of thickened epithelium accompanied
by sebaceous gland hyperplasia as evident by multiple glands associated with each hair follicle
(arrows). (C) Liver of an M control mouse (40X) with the normal lobular architecture (P =
portal region; M = midzonal region; C = centrilobular region). (D) Liver of a KM experimental
mouse (40X) with marked extramedullary hematopoiesis corresponding to the basophilic cell
infiltrate evident primarily in the portal and centrilobular areas. (E) Spleen of an M control
mouse (100X) with the normal architecture, characterized by white (W) and red (R) pulp. (F)
Spleen of a KM experimental mouse (40X) with marked extramedullary hematopoiesis
expanding the red pulp (R) and lymphohistiocytic proliferation obscuring the white pulp (W).
and M) such that the median survival for both experimental cohorts was approximately 90 days
(Figure 2.2). However, there was no significant difference in survival between the two
experimental cohorts, KPM and KM (p = 0.8). These data indicate that the Peg3del6 allele in
KPM mice did not have any additional effect on survival. Both negative control cohorts did not
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show any signs of distress, and remained healthy throughout the duration of the experiment.
Furthermore, both experimental cohorts, KPM and KM, experienced significant burden due to
increased size of liver (8.0±1.1%, p < 0.001 and 11.3±1.8, p < 0.001, mean percent of body
weight respectively), spleen (3.0±1.5%, p < 0.001 and 5.1±1.5 %, p < 0.001, mean percent of
body weight respectively) and thymus compared to those of negative control littermates (Figure
2.2). Thymus data were not collected due to the size reduction of this organ as the negative
control mice age. In KPM and KM mice, the pressure imposed by the over-sized liver and spleen
most likely resulted in abdominal pain, and the pressure imposed by the over-sized thymus most
likely caused partial lung collapse resulting in shortness of breath and lethargy. Furthermore,
histopathological analyses of the liver and spleen revealed that these two organs had marked
extramedullary hematopoiesis accompanied, in the spleen, by lymphohistiocytic proliferation in
the white pulp (Figure 2.3). In summary, expression of KrasG12D was primarily responsible for
the observed phenotypes and expression of Peg3del6 did not enhance or contribute to these
phenotypes.
The mice expressing KrasG12D developed an infiltrative thymic neoplasm. One-month-old
mice had marked expansion of the cortex by a heterogeneous cell population composed of small
and large lymphocytes (Figure 2.4). Older, three-month-old, mice had the thymic architecture
completely effaced by dense sheets of neoplastic lymphoid cells morphologically consistent with
lymphoblast (Figure 2.4) [19,20,21,22]. Furthermore, neoplastic cells were CD3 positive and
PAX5 negative (Figure 2.4). Neoplastic cells variably infiltrated the adjacent adipose tissue, the
dorsal root ganglia, the myocardium at the base of the heart, the wall of the ventral (sternum) and
dorsal thorax, and the ventral neck musculature (Figure 2.4).
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The percent of mice developing lymphoblastic T-cell thymic lymphoma was similar for both
experimental cohorts, KPM and KM, each at 40%. This could be explained by the fact that antiPEG3 staining in control and experimental mice was negative suggesting that PEG3 is not
produced in any cell type within the thymus (Figure 2.5). Because previous studies have
IHC for CD3
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Figure 2.4. Histological thymic alterations in KM mice. (A) The cortex is expanded by a
heterogeneous (hyperplastic) lymphoid cell population, with retention of the normal thymic
architecture in a 1-month-old KM mouse. (B) The architecture of the hyperplastic thymus in a 1month-old KM mouse is maintained, with the majority of CD3 immunopositive cells in the
cortex. (C) The normal architecture of the thymus is completely effaced by a lymphoid round
cell neoplasm in a 2.5-month-old KM mouse. (D) Neoplastic lymphoid cells effacing the thymus
in a 2.5-month-old KM mouse are diffusely CD3 immunopositive, consistent with T-cell origin
of the neoplasm. (E-G) H&E staining of nearby tissues. (E) Neoplastic cells invade adjacent
adipose tissue. (F) Neoplastic cells encircling ganglia. (H) Neoplastic cells invade the
myocardium at the base of the heart (G) Neoplastic cells invade the musculature of the sternum.
All insets show to neoplastic cells at 400X.
suggested that Yin-yang 1 (YY1) may be a suppressor of Peg3 expression, we also performed
anti-YY1 staining; however, similar to the anti-PEG3 staining, YY1 was not detected in any cell
population within the thymus (Figure 2.5). Thus, these data indicate that the KrasG12D mutation is
sufficient to initiate the development of an infiltrative T-cell neoplasm within the mouse thymus,
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and that the Peg3del6 mutation does not enhance the latency of KrasG12D-induced T-cell
lymphoma.
Invasive

Pre-invasive

Normal Testes
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Figure 2.5. Neither PEG3 nor YY1 protein is produced in the thymus. (A-F) Representative
immunohistochemistry from anti-PEG3 and anti-YY1 staining of positive control tissue (testis),
hyperplastic tissue (thymus) and neoplastic tissue (thymus). (A&B) Immunostaining of testis
confirms the efficacy of the PEG3 and YY1 antibodies, respectively. (C&D) Immunostaining of
thymus containing a hyperplastic cell population from a L-KrasG12D;MMTV-Cre (KM) mouse
can not detect PEG3 or YY1 proteins, respectively. (E&F) Immunostaining of thymus containing
neoplastic cell population from a KM mouse can not detect PEG3 or YY1 proteins, respectively.
DNA methylation changes at ICRs during progression of KrasG12D-induced lymphoblastic Tcell thymic lymphoma. For DNA methylation analyses, 15 experimental samples of the thymus
(12 from KM mice and 3 from KPM mice) were selected: five hyperplastic, five atypically
hyperplastic and five neoplastic lesions as determined from clinical and pathological
observations. The DNA methylation profiles of the experimental tissue samples were compared
to those of negative control samples from the M cohort. Combined Bisulfite Restriction Analysis
was used to initially screen for DNA methylation differences (COBRA, [23]). This series of
analyses derived the following observations. First, significant changes in DNA methylation were
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more frequently observed within ICRs than the promoters of Tumor Suppressor Genes (TSG).
For example, five ICRs (Ig, Peg10, Peg3, Nespas, and Grb10) were significantly
hypermethylated, whereas only two TSG promoters (Mgmt and Fhit) were significantly
hypermethylated, in the most advanced tumor sample (Figure 2.6). The most affected was the IgICR, showing significant hyper-methylation in 73% of the samples. In contrast,
hypermethylation within promoters of the most affected TSGs, Mgmt and Fhit, was only
detected in 20% of the samples. Collectively, 60% of DNA from lymphoblastic T-cell thymic
lymphoma displayed aberrant DNA methylation in two or more ICRs, whereas only 6% of these
DNA displayed aberrant DNA methylation in two or more TSG promoters (Figure 2.6).
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Figure 2.6. Signature of aberrant DNA methylation in KrasG12D-induced lymphoblastic thymic Tcell lymphoma. Heat map summary of the quantified COBRA data for all ICRs tested in 15
thymic samples. Based on p values from pairwise T-test, each locus tested in the thymic samples
was determined to be hypermethylated (red), hypomethylated (green), or not changed (grey).
The gradation of yellow in the sample # column depicts progression of the disease state from
hyperplastic (white) to atypically hyperplastic to neoplastic (yellow).
Second, the majority of changes observed in ICRs were hypermethylation. Only the Peg10ICR displayed either hyper- or hypo-methylation among 60% of the samples. In this case, the
frequency of hypermethylation was 0.13, whereas the frequency of hypomethylation was 0.47.
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Interestingly, hypomethylation of the Peg10-ICR was the only detectable change in three out of
the five hyperplastic samples (Figure 2.6). Thus, these data indicate that aberrant DNA
methylation in the Peg10-ICRs may be one of the first detectable changes in lymphoblastic Tcell thymic lymphoma.
Third, several tumor samples displayed both hyper- and hypo-methylation in the tested ICRs

Mean methylation (%)

(Figure 2.7). In sample 6, the mean percent methylation of the Peg10-ICR reduced to 29±4%

IG-ICR

Grb10-ICR

Peg10-ICR

H19-ICR

Nespas-ICR

Igf2-DMR1

Thymus sample

Figure 2.7. DNA methylation profiles of DMRs in thymic lymphoma. Mean percent methylation
generated by COBRA of imprinting control regions and differentially methylated regions within
imprinted domains that displayed significant changes among 16 thymus samples: 1 normal
sample (N) and 15 experimental samples expressing KrasG12D (1-15).
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(p = 0.006), yet mean percent methylation drastically increased to 84±2% (p < 0.001) in the IgICR and 87±6% (p < 0.001) in the Peg3-ICR (Figure 2.7 and Figure 2.8). These coexisting
hyper- and hypo-methylation data indicate that changes within ICRs are not the result of global
changes to the methylome towards hypermethylation at CpG islands; rather, these changes are
the result of discrete events. In summary, these data demonstrate that aberrant DNA methylation
within ICRs is precocious and dynamic in T-cell lymphoma. The complete set of mean percent
methylation graphs for each ICR and DMR with significant changes is available (Figure 2.7 and
Figure 2.8).
DNA methylation changes at distal enhancers within imprinted domains during progression
of KrasG12D-induced lymphoblastic T-cell thymic lymphoma. We also surveyed DNA
methylation in other regulatory regions within imprinted domains. First, we measured DNA
methylation changes at distal enhancers since these elements are known to be vulnerable during
carcinogenesis [24]. For this test, we measured the DNA methylation levels of a putative
enhancer found within the Peg3 domain, termed ECR18 (Figure 2.8) [25]. According to the
results, the Peg3-ICR displayed significant hypermethylation in 6 out of 15 samples (#2, 4, 6, 8,
10, and 14), and Peg3-ECR18 displayed significant hypermethylation in 7 out of 15 samples (#2,
6, 7, 8, 9, 12 and 14). Interestingly, sample #7 displayed similar methylation levels at both the
Peg3-ICR (62±9%) and Peg-ECR18 (55±12%). However, the change in methylation was only
significant for Peg3-ECR18 due to the low level of methylation at the enhancer region and 50%
methylation at the ICR in normal tissue. Furthermore, the Peg3-ECR18 displayed significant
hypermethylation in samples #9 and #12 while the ICR remained unaffected suggesting that the
enhancer region acquired DNA methylation changes before the ICR.
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Figure 2.8. Distal enhancer regions may prove to be effective biomarkers. (A-B) Aberrant DNA
methylation comparison of the Peg3-ICR and the Peg3-ECR18. (A) COBRA of the Peg3-ICR.
(B) COBRA of the Peg3-ECR18. Unmethylated DNA is denoted with a U. Methylated DNA is
denoted with a M. Stars represent significant increases in DNA methylation compared to normal
DNA (denoted by the letter N). Experimental samples are numbered 1-15. Red represents
hypermethylation, grey represents no change, and blue represents normal/control levels.
Second, we also surveyed the DNA methylation levels of the differentially methylated region
(DMR) and promoter for the two imprinted genes, Gnas and Dlk1 (Figure 2.9). Interestingly,
neither the DMR nor the promoter for either gene displayed any changes in DNA methylation.
However, the ICRs for both genes frequently experienced significant changes. The ICR for the
Gnas domain, Nespas-ICR, was hypermethylated in 3 out of 15 samples and the ICR for the
Dlk1/Gtl2 domain, Ig-ICR, was hypermethylated in 11 out of 15 samples (Figure 2.9). These
data demonstrate that ICRs are more sensitive to DNA methylation changes than DMRs or
promoters. Taken together, these results demonstrate that ICRs and enhancer elements are both
more sensitive to DNA methylation changes than DMRs or promoters, and that changes in
methylation within enhancer elements may be more readily detectable.
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Figure 2.9. Aberrant DNA methylation is targeted to ICRs within imprinted domains. Images
generated from COBRA analysis of three regulatory regions within the Gnas and Dlk1/Gtl2
domains. For each domain, the ICR, a nearby DMR and a nearby promoter were measured.
Unmethylated DNA is denoted with a U, while methylated DNA is denoted with an M. The
enzymes used to digest each amplicon are presented under the name of each PCR product.
Bisulfite sequencing revealed hypermethylation-resistant CpG sites within ICRs. We also
performed NGS-based bisulfite sequencing for a subset of the PCR products to get a more
holistic view of DNA methylation changes. PCR products were selected from seven
experimental samples (4 KM and 3 KPM) and one control sample (N). Results from the Peg3ICR are displayed as a representative set (Figure 2.10). Inspection of the sequencing results
allowed for the following observations. First, sequencing results were mostly consistent with the
results generated by COBRA, confirming that there was a correlation between DNA methylation
levels and the degree of tumor progression in the tested samples (Figure 2.6 and Figure 2.10). In
the hyperplastic sample (#13), the DNA methylation pattern was consistent with the pattern in
the control sample (N), where approximately one half of the heat map was red (denoting
methylated CpG sites) and the other half was blue (denoting unmethylated CpG sites). This is the
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Figure 2.10. Bisulfite NGS reveals not all CpG are equally vulnerable to DNA methylation
changes. Heat maps generated by BiQ analyzer HT showing DNA methylation at each CpG
(Nos. 1-16) within bisulfite PCR products. Results from the Peg3-ICR are shown as a
representative set. Each column represents a CpG within the bisulfite PCR product and each row
represents a sequencing read. The positions of the restriction sites utilized in COBRA are
indicated below the heat map of the control sample (N) with triangles (black for TaqαI and purple
for HphI). Mean methylation (%) and number of reads are presented above each map. Below the
heat maps is a UCSC genome browser view of putative CSEl containing CpGs Nos. 4-7.
Sequences are highlighted based on matching the consensus motif of the SP1 transcription factor.
An expansion of CSE1 is proposed based on the most hypermethylation resistant CpG, #3, being
contained in a highly conserved region that matched very well with the SP1 binding motif and
was not included in putative CSE1.

35

typical pattern generated by normal levels of DNA methylation due to ICRs being methylated on
one allele and unmethylated on the other. However, the normal pattern was no longer present in
neoplastic samples such as #2, representing the most advanced tumor. This sample was
hypermethylated to such an extent that mean methylation was nearly 84%, which rendered the
portion of the heat map representing the unmethylated allele virtually non existent (Figure 2.10).
Second, certain CpG sites were resistant to DNA methylation change. Within the amplicon
for the Peg3-ICR, this trend was evident by a subset of CpG sites maintaining the normal half red
and half blue pattern even though other CpG sites were methylated in 90% or more of
sequencing reads. The CpG sites particularly maintaining the normal pattern were Nos. 3,4,7,12
and 13 (Figure 2.10). Inspection of the sequences surrounding these resistant CpGs indicated that
these sites are part of potential regulatory sequences. CpG Nos. 3,4 and 7 are part of the GC-box
motif, 5’- GGGCGG -3’, and CpG Nos. 12 and 13 are part of the palindrome, 5’- CGATCG -3”.
Two of the CpGs Nos. 4 and 7 are within a putative conserved sequence element (CSE1) that is
known to attract an unknown repressive protein complex to the Peg3-ICR [26,27]. Interestingly,
another conserved GC-box motif happens to be localized just outside CSE1, yet this is the motif
housing the most resistant CpG site No. 3 based on its methylation status most evident in the heat
map for sample #2 (Figure 2.10). Overall, this series of analyses demonstrated that DNA
methylation changes expand during tumor progression and that certain CpG sites might be
protected from DNA methylation changes potentially due to the binding of unknown
transcription factors.
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2.3 Discussion
Analyses of many human cancers suggest that the methylation status of genomic imprinting
is challenged during carcinogenesis and that loss of imprinting (LOI) contributes to neoplastic
transformations [12]. However, the context (i.e., the causative genomic mutation) in which DNA
methylation changes occur within imprinted domains can rarely be determined. Furthermore, it
may not be possible to determine which mutation, the genomic or the epigenomic, is established
first in sporadic human tumors. Further complicating matters, DNA methylation signatures
within imprinted domains vary from one tumor type to the next [8]. Therefore, it is necessary to
survey DNA methylation of imprinted domains in various tumor types in which the causative
genomic mutation is known. Here, we induced lymphoblastic T-cell thymic lymphoma in mice
using the KrasG12D oncogene and systematically surveyed for aberrant DNA methylation within
imprinted domains. With this study, we show that DNA methylation in imprinted domains is
frequently challenged in T-cells expressing KrasG12D (Figure 2.6) and that DNA methylation
changes do not occur equally within an imprinted domain. Rather, these changes occur most
frequently at ICRs (or “control DMRs”) and enhancers (Figure 2.7 and Figure 2.9) of imprinted
domains. Furthermore, we found that certain evolutionarily conserved sequence elements that
attract DNA binding proteins are resistant to DNA methylation changes (Figure 2.10). Overall,
the ICRs of the Peg10, Dlk1/Gtl2 and Peg3 domains experienced the most notable DNA
methylation changes in T-cell lymphoma (Figure 2.6).
Aberrant DNA methylation within the Peg10 and Dlk1/Gtl2 domains has also been reported
in human B-cell leukemias and malignancies [8]. The consistency of these two domains
experiencing changes in both B-cell and T-cell neoplasms has several implications. First,
detecting DNA methylation changes cannot be used to determine the cell type responsible for
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lymphocytic tumors. However, detection of aberrant DNA methylation within imprinted domains
may provide insight into the severity of a disease. For instance, while the only detectable
changes in hyperplastic tumors occurred in the Peg10 and Dlk1/Gtl2 domains, changes were
frequently detected within several other domains such as Peg3 in neoplastic tumors (Figure 2.6).
Thus, detection of aberrant DNA methylation in imprinted domains other than Peg10 and
Dlk1/Gtl2 suggests lymphocytes have already undergone neoplastic transformation. Second,
because the Peg10 and Dlk1/Gtl2 domains experience detectable changes in hyperplastic tumors,
changes in these domains may contribute to neoplastic transformation. If this does prove to be
the case, then specific therapeutic modalities may be designed to restore normal DNA
methylation settings within these domains. Lastly, neither the causative genomic mutation nor
the specific cell type may be directly responsible for changes in DNA methylation. Rather,
distinct DNA methylation signatures are likely established based on whether or not the
epimutation provides a selective advantage for a given tumor cell.
ICRs contain a variety of DNA sequence elements that have been linked to hyper- and
hypomethylation trends, which are notorious for increasing cancer heterogeneity [28, 29]. These
sequence elements include tandem repeats, CpG islands, and ncRNA promoters, all of which
often co-exist within an ICR [1]. For instance, while CpG islands tend to attract
hypermethylation, tandem repeat sequences frequently become hypomethylated [28]. Thus, any
given ICR has the potential to either gain or lose methylation. This phenomenon is showcased
quite nicely by our analysis of the Peg10-ICR. The Peg10-ICR was hypomethylated in seven
samples and hypermethylated in two samples among the nine T-cell neoplasms that displayed
DNA methylation changes within this region. PEG10 has been derived from retrotransposons,
which may account for the frequent hypomethylation. At the same time, the ICR of the Peg10
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domain contains a CpG island, which may account for the hypermethylation. Therefore, the
unusual clustering of various sequence elements within ICRs may be what first attracts DNA
methylation changes. Most often, the changes that occur at ICRs will not contribute to disease
progression. However, when certain epimutations at ICRs do contribute to the carcinogenesis of
a particular tumor cell type, they can be selected for and propagated by rapidly dividing tumor
cells until the epimutation is fixed in what now can be considered an evolved population of
tumor cells.
DNA methylation changes are primarily restricted to ICRs within an imprinted domain.
Invasive breast cancer frequently displays aberrant DNA methylation within several imprinted
domains and loss of imprinting does not necessarily accompany DNA methylation changes [30].
However, it is still unclear whether the observed methylation changes could be the result of
shifting DNA methylation boundaries or specific DNA methylation changes contained within
imprinted domains [30]. According to the results of our analyses of the Dlk1/Gtl2 and Gnas
domains, the ICRs of these domains frequently experienced aberrant DNA methylation, but
regions outside of the ICRs (i.e., nearby DMRs and promoter regions) were not affected (Figure
2.7). Therefore, we believe that DNA methylation changes are not the result of shifting DNA
methylation pattern. Rather, aberrant DNA methylation is confined to certain regions of
imprinted domains, particularly ICRs.
ICRs are unusually sensitive to DNA methylation changes during carcinogenesis, but there
may be other regions of the genome that are just as sensitive. While surveying the Peg3 domain,
we observed that an evolutionarily conserved region (ECR18), a putative enhancer for the Peg3
domain, was hypermethylated at a similar frequency even though it is 200 kb upstream from the
Peg3-ICR (Figure 2.9). Although this observation implies that enhancer regions may also be

39

unusually sensitive to DNA methylation changes during carcinogenesis, further investigations
into several other enhancer regions are needed to confirm this preliminary observation. However,
this observation is consistent with recent reports that demonstrated DNA methylation of
transcriptional enhancers is associated with cancer predisposition [31]. It will certainly be
interesting to further investigate how changes in DNA methylation at enhancer regions can
impact nearby gene expression profiles within tumor cells and how such changes contribute to
carcinogenesis. If enhancer regions do prove to be particularly vulnerable to DNA methylation
changes in tumor cells, they could make excellent biomarkers given their ubiquitous distribution
in the genome.
Bisulfite sequencing analyses revealed that DNA methylation changes are not only variable
among ICRs, but also variable within a single ICR. For instance, while the sequencing results
were consistent with the COBRA results, they also revealed an unexpected pattern in tumor cells.
Certain CpG sites remained unaffected even though neighboring CpG sites experienced
extensive hypermethylation. Upon close inspection of the immediate sequences surrounding the
resistant CpG sites, we noticed that these sites are within the GC-box motif, 5’- GGGCGG -3’
(Figure 2.10). There are two possibilities that may be responsible for this trend. First, certain
CpG sites remain unaffected due to the binding of unknown transcription factors, which may
have a role in genomic imprinting or transcription of imprinted genes within the region. Second,
the unaffected CpGs may simply be within DNA segments that are less accessible to the DNA
methyltransferase machinery due to nucleosome occupancy. Since the only observed resistant
sites were part of well-known consensus sequences, we favor the first scenario that these CpG
are shielded from DNA methylation because of being bound by proteins. However, we plan to
further investigate this hypothesis in the near future.
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Previously, we have identified a conserved sequence element (CSE1) within the Peg3
domain. According to the results, an unknown protein complex binds to CSE1, and this complex
is predicted to be a strong repressor for the expression of Peg3 [26,27]. Upon close inspection of
the CpG sites (Nos. 4-7) of the Peg3-ICR amplicon, which are localized within putative CSE1,
we realized CpGs sites Nos. 4 and 7 are part of a well-known motif, the GC-box. Oddly, there
was a CpG site (No. 3) immediately outside the 42-bp-putative CSE1 sequence that is also part
of a GC-box motif. Interestingly, this CpG site was most resistant to DNA methylation and is
highly conserved among placental mammals (Figure 2.10). Furthermore, when we included the
slightly degenerate sequences surrounding the core sequence of the GC box, we noticed a
surprising trend: these evolutionarily conserved sequences fit very well with the consensus
sequence, 5'-(G/T)GGGCGG(G/A)(G/A)(C/T)-3', known to be bound by the SP1 transcription
factor [32] (Figure 2.10). The CpG sites within this consensus sequence resisting DNA
methylation change is consistent with a previous study which reported that the SP1 protein
protects CpG islands from de novo DNA methylation [33]. Although this observation suggests
SP1 as a possible candidate protein binding to this region, further testing is required to support
the hypothesis that SP1 binds to CSE1 and subsequently regulates Peg3 expression. Nonetheless,
the current results suggest that the previously defined region of CSE1 may need expansion to
include the outlying GC-box as a conserved cis-regulatory module (Figure 2.10).
To our knowledge, this is the first study to challenge murine cells with a potent oncogenic
mutation and then systematically survey imprinted domains for aberrant DNA methylation. The
results from the DNA methylation analyses of this study demonstrate that the DNA methylation
status of ICRs is unstable and that aberrant DNA methylation accumulates among several ICRs
during carcinogenesis of lymphoblastic T-cell thymic lymphoma. Whether the observed DNA
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methylation changes within ICRs directly contribute to the development of a tumor cell
population or are merely the result of the accumulation of changes over time in the tumor cell
methylome is still unknown and requires further investigation. However, considering that the
function of many imprinted gene products is frequently associated with physiological cellular
processes such cell growth and death and how sensitive imprinted genes dosage is to these
physiological processes, it is likely that changes within ICRs for a subset of imprinted genes such
as Peg10, Dlk1, Gnas, and Peg3 could alter gene expression and tip the scales such that a tumor
cell population could gain a competitive edge and proliferate with fewer checks and boundaries.

2.4 Materials and Methods
Three mouse stains were maintained for the duration of the experiment. Two publically
available mouse strains, B6.129-Krastm4Tyj/Nci (LSL-KrasG12D) and STOCK Tg(MMTVCre)4Mam/J (MMTV-Cre), were purchased from Jackson Laboratories [13,14,15]. The third
strain, Peg3floxed, was generated in the lab [16,17]. The order of breeding was carried out as
follows: first, the Peg3floxed allele was bred with the LSL-KrasG12D model to generate double
heterozygous mice. Next, male double heterozygous mice for Peg3floxed and LSL-KrasG12D were
bred with female homozygous MMTV-Cre mice. This breeding scheme yielded progeny with
four different genotypes: KPM, KM, PM, and M. All experiments were performed in
accordance with National Institutes of Health guidelines for care and use of animals, and also
approved by the Louisiana State University Institutional Animal Care and Use Committee
(IACUC), protocol #13-061.
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All litters were weaned 21 days post partum and littermates were separated by gender based
on comparing the relative distance of the genitalia from the perianal membrane. No more than
five littermates were housed in a single cage. Littermates were identified through varying
positions of a hole punch on the left ear. Genomic DNA from a right ear clip was used for PCR
genotyping. Ear clips were lysed overnight at 60ºC in a solution with tail lysis buffer (Tris-HCl
pH 8.1 100 mM, EDTA 5 mM, NaCl 200 mM, SDS 0.2%) supplemented with Proteinase K
(NEB, Cat. No. P8107S). Lysates were diluted at 1:60 with nanopure water. Two microliter of
diluted lysate was directly added to Maxime PCR Premix tubes (intron, Cat. No. 25167)
followed by 1 µl of primer at the concentration of 10 pM and nanopure water to bring the
reaction to 20 µl. The following specific primer sets were used for each of the following mouse
strains: Peg3FlpKo/Del6: Peg3 5arm 5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’ and Peg3 LoxR
5’-TGAACTGATGGC GAGCTCAGACC-3’ and Peg3 rev 5’ACCCCATTCTCATCAGCTCCAGAG-3’; MMTV-Cre: MMTV-Cre F 5’-CTGATCT
GAGCTCTGAGTG-3’ and MMTV-Cre R 5’-CATCACTCGTTGCATCGACC-3’; LSLKrasG12D: Kras F1 5’-GTCTTTCCCCAGCACAGTGC-3’ and Kras Fcass 5’AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’; L-KrasG12D: Kras F1 5’GTCTTTCCCCAGCACAGTGC-3’ and Kras R1 5’-CTCTTGCCTACGCCAC CAGCTC-3’.
Genotyping PCR conditions for 33 cycles were as follows: denaturation at 95ºC for 30 seconds,
annealing at 60ºC for 30 seconds, and extension at 72ºC for 1 minute.
Mice were sacrificed by CO2 asphyxiation in accordance with the rules and regulations set
forth by the IACUC either when showing signs of distress or when reaching 15% weight loss
(weight measurements were taken every three days for mice expressing the KrasG12D mutation).
A full necropsy was performed on all mice. Tissues were fixed in 10% neutral buffered formalin
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(Thermo Scientific, Cat. No. 5725) for at least 48 hours, and then transferred to 70% ethanol for
storage. Tissues were trimmed and embedded in paraffin, sectioned, and stained with
hematoxylin and eosin (H&E). Sections were evaluated by a board-certified veterinary
pathologist (IML). Samples of oral, anal and foot pad masses and any other tissue that appeared
grossly abnormal were also placed in lysis buffer containing Proteinase K for subsequent DNA
extraction and analyses. The standard method was used for immunohistochemistry. Briefly,
paraffin blocks were sectioned at 5 µm and deparaffinized (three xylene changes, 5 min each;
three washes with 100% ethanol, 4 min each; one wash with 95% EtOH, 4 min; one dH2O rinse;
and one buffer rinse). Slides were soaked in 3% H2O2/dH2O for 10 min to quench endogenous
peroxidase activity, and were incubated with normal goat blocking serum for 30 min. Antigenretrieval was performed with a Biocare Decloaker for 20 min in DAKO citrate buffer pH 6.
Primary antibodies were diluted with the DAKO antibody diluent, and were applied at room
temperature for 30 minutes for anti-CD3 (Santa Cruz Biotechnology, Cat. No. sc-1127), antiPAX5 (Santa Cruz Biotechnology, Cat. No. sc-1974) and anti-Peg3 [17], and one hour for antiYY1 (Santa Cruz Biotechnology, Cat. No. sc-7341). The following primary antibody dilutions
were used: anti-CD3 (1:350), anti-PAX5 (1:300), anti-Peg3 (1:50), and anti-YY1 (1:100).
Biotinylated anti-goat in rabbit and biotinylated anti-rabbit in goat secondary antibodies were
diluted with the DAKO antibody diluent and applied to the slides. Slides were counterstained
with Hematoxylin. Staining was performed on a DAKO Autostainer Link 48.
Genomic DNA was purified from mediastinal tissue samples by spin column recovery
(Genomic DNA clean and concentrator-25, Zymo Research, Cat. No. D4065). Purified genomic
DNA (500 ng) from each mediastinal lesion was bisulfite-converted using a commercial kit (EZ
DNA methylation kit, Zymo Research, Cat. No. D5002). The converted DNA was used for PCR
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amplification. The detailed information regarding the sequences and genomic position for each
oligonucleotide set has been presented as (table 2.1). The amplified PCR products from
bisulfite-converted DNA were digested with restriction enzymes, separated on a 2% agarose gel,
and the relative amount of each digested DNA fragment was measured based on its band density
as described below. QuantityOne software was used to export gel electrophoresis images as
lossless tiff files (Gel Doc system, BioRad). Tiff files were then processed as 8-bit grayscale
using ImageJ software [34] in the following manner: 1) data was inverted; 2) background was
subtracted using default setting; 3) brightness/contrast was adjusted by selecting the auto adjust
command one time; 4) bands in each lane were selected individually using the rectangular tool;
5) density plots were then generated for each rectangular selection; 6) each density peak was
gated at the base of the peak at a location higher then background signals using the line drawing
tool; and 7) the area under each peak was automatically generated by the software using the
wand tool. Area results were exported into an Excel spreadsheet where all subsequent analyses
were performed. DNA Methylation values (%) were calculated using the following formula:
100*((area of peak from digested DNA/s)/(area of peak from digested band/s + area of peak
from undigested DNA)). ANOVA (single factor) statistical analysis was performed on the
percent methylation results for each locus screened. If the p value from the ANOVA analysis
was less than or equal to 0.05, then subsequent pair wise T-test (two sample assuming equal
variance) was performed comparing each tumor sample to normal tissue for each locus. Three
independent trials starting from bisulfite conversion to restriction digestion were repeated to
derive the average DNA methylation levels of each locus within 95% confidence intervals.
Sequencing of the individual bisulfite PCR products was performed using a NGS platform
(PGM2, Ion Torrent, Life Technologies). Briefly, bisulfite PCR products for each locus from
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each trial were pooled for seven representative thymic lesions, and for one control thymus. End
repair was performed using a commercially available module (NEBNext End Repair Module,
Cat. No. E6050S). End-repaired bisulfite PCR products were then visualized by electrophoresis,
size-selected, and extracted using a commercially available kit (Gel DNA recovery kit, Zymo
Research, Cat. No. D4001). Barcoded adapters were ligated to each thymic lesion’s pooled
bisulfite PCR products by the activity of two enzymes in concert (Bst 2.0 WarmStart, NEB, Cat.
No. M0538S and T4 DNA ligase, NEB, M0202S). The adapter ligation reactions were
visualized with gel electrophoresis, and the products were extracted using the Zymo kit
referenced above. PCR with primers specific for the adapters was used to enrich for the PCR
products that had the proper adapter orientation. The enriched PCR products were then
submitted to the genomics core facility at Louisiana State University (LSU) for sequencing. The
raw sequence reads were processed in the following manner. Briefly, Sequence reads smaller
than 100 bp in length were discarded. The remaining sequences were first sorted by bar code for
each thymic lesion, and then sorted by the primer sequences specific for each PCR product such
that forward and reverse reads were sorted into the same directory. The BiQ Analyzer HT tool
was used to further process the sorted sequences such that reads with greater than or equal to
80% bisulfite conversion and 50% sequence identity were analyzed to calculate DNA
methylation levels for each locus [35]. The bioinformatics pipeline used for this process is
available upon request.
For each animal, date of birth and date of necropsy were recorded and compared by Kaplan
Meyer survival analyses of the four cohorts using GraphPad Prism Version 4.0 software.
However, for ease of formatting, Microsoft Excel was used to generate the survival curve graph.
Upon necropsy, each animal’s body, liver, spleen and right kidney weights were measured using
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a thermo scientific digital scale with 0.001g accuracy. Data was imported into Microsoft Excel
and was processed in the following manner. Each organ’s percent of body weight was calculated
mean % weight = 100*(weight of organ/total body weight). For each cohort, mean percent
weight of kidney, spleen and liver was calculated and plotted with 95% confidence intervals.
ANOVA (single factor) was used to compare the percent weights of each organ type among the
four cohorts. If the p-value from the ANOVA analysis was less than or equal to 0.05, then
subsequent pairwise T-tests (two sample assuming equal variance) were performed to compare
each cohort to one another for each organ type.

2.5 References
1. Bartolomei MS, Ferguson-Smith AC. (2011) Mammalian genomic imprinting. Cold Spring
Harb Perspect Biol 3:pii: a002592. doi: 10.1101/cshperspect.a002592.
2. Barlow DP, Bartolomei MS. (2014) Genomic imprinting in mammals. Cold Spring Harb
Perspect Biol 6:pii: a018382. doi: 10.1101/cshperspect.a018382.
3. Relaix F, Wei XJ, Li W, Pan J, Lin Y, Bowtell DD, et al. (2000) Pw1/Peg3 is a potential cell
death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci
USA 97(5): 2105–2110. doi: 10.1073/pnas.040378897
4. Reik W, Davies K, Dean W, Kelsey G, Constância M. (2001) Imprinted genes and the
coordination of fetal and postnatal growth in mammals. Novartis Found Symp 237: 19-31;
discussion 31-42. doi: 10.1002/0470846666.ch3.
5. Rezvani G, Lui JC, Barnes KM, Baron J. (2012) A Set of Imprinted Genes Required for
Normal Body Growth Also Promotes Growth of Rhabdomyosarcoma Cells. Pediatr Res
71(1): 32-8. doi: 10.1038/pr.2011.6.
6. Lim DH, Maher ER. (2010) Genomic imprinting syndromes and cancer. Adv Genet 70:145175. doi: 10.1016/B978-0-12-380866-0.60006-X.
7. Uribe-Lewis S, Woodfine K, Stojic L, Murrell A. (2011) Molecular mechanisms of genomic
imprinting and clinical implications for cancer. Expert Rev Mol Med 13: e2. doi:
10.1017/S1462399410001717.

47

8. Monk D. (2010) Deciphering the cancer imprintome. Brief Funct Genomics 9(4): 329-39.
doi:10.1093/bfgp/elq013.
9. Bartolomei MS. (2009) Genomic imprinting: employing and avoiding epigenetic processes.
Genes Dev 23(18): 2124–2133. doi: 10.1101/gad.1841409.
10. Spahn L, Barlow DP. (2003) An ICE pattern crystallizes. Nat Genet 35: 11–12. doi:
10.1038/ng0903-11.
11. Plass C, Soloway PD. (2002) DNA methylation, imprinting and cancer. Eur J Hum Genet
10(1): 6-16. doi: 10.1038/sj/ejhg/5200768
12. Jelinic P, Shaw P. (2007) Loss of imprinting and cancer. J Pathol 211(3): 261-8. doi:
10.1101/gad.943001.
13. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. (2001) Analysis
of lung tumor initiation and progression using conditional expression of oncogenic K-ras.
Genes Dev 15: 3243-3248. doi: 10.1101/gad.943001
14. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A., et al.
(2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.
Nature 410: 1111– 1116. doi :10.1038/35074129.
15. Kim J, Frey WD, He H, Kim H, Ekram MB, Bakshi A, et al. (2013) Peg3 mutational effects
on reproduction and placenta-specific gene families. PLoS One 8(12): e83359.
doi:10.1371/annotation/8de03ec5-e62c-4135-87ee-4928475090a8.
16. Perera BP, Teruyama R, Kim J. (2015) Yy1 gene dosage effect and bi-allelic expression of
Peg3. PloS one 10(3): e0119493. doi: 10.1371/journal.pone.0119493.
17. Wagner K, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, et al. (1997)
Cre-mediated gene deletion in the mammary gland. Nuc Acids Res 25: 4323–4330.
doi:10.1172/JCI200420476.
18. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L. (2001) Spatial
and temporal expression of the Cre gene under the control of the MMTV-LTR in different
lines of transgenic mice. Transgenic Res 10(6): 545-53. doi: 10.1023/A:1013063514007.
19. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. (2004) Conditional
expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative
disease. J Clin Invest 113: 528-538. doi: 10.1172/JCI200420476.
20. Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, et al. (2013) Notch1 gene
mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic
transformation. J Biol Chem 288(25): 18219-27. doi: 10.1074/jbc.M113.475376.

48

21. Pearse G. (2006) Histopathology of the thymus. Toxicol Pathol 34(5): 515-47. doi:
10.1080/01926230600978458.
22. Ward JM. Lymphomas and leukemias in mice. Exp Toxicol Pathol 57(5-6): 377-81.
doi:10.1016/j.etp.2006.01.007.
23. Xiong Z, Laird PW. (1997) COBRA: a sensitive and quantitative DNA methylation assay.
Nucleic Acids Res 25: 2532-2534. doi: 10.1093/nar/25.12.2532.
24. Aran D, Sabato S, Hellman A. (2013) DNA methylation of distal regulatory sites
characterizes dysregulation of cancer genes. Genome Biol 14(3): R21. doi: 10.1186/gb-201314-3-r21.
25. Thiaville MM, Kim H, Frey WD, Kim J. (2013) Identification of an evolutionarily conserved
cis-regulatory element controlling the Peg3 imprinted domain. PLoS One 8:e75417. doi:
10.1371/journal.pone.0075417.
26. Kim J, Kollhoff A, Bergmann A, Stubbs L. (2003) Methylation-sensitive binding of
transcription factor YY1 to an insulator sequence within the paternally expressed imprinted
gene, Peg3. Hum Mol Genet 12(3): 233-45. doi: 10.1093/hmg/ddg028.
27. Kim JD, Yu S, Choo JH, Kim J. (2008) Two evolutionarily conserved sequence elements for
Peg3/usp29 transcription. BMC Mol Biol 10; 9:108doi: 10.1186/1471-2199-9-108.
28. Ehrlich M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene
21(35): 5400-5413. doi:10.1038/sj.onc.1205651.
29. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 31(1): 27-36. doi:
10.1093/carcin/bgp220.
30. Barrow TM, Barault L, Ellsworth RE, Harris HR, Binder AM, Valente AL, et al. (2015)
Aberrant methylation of imprinted genes is associated with negative hormone receptor status
in invasive breast cancer. Int J Cancer 137(3): 537-47. doi: 10.1002/ijc.29419.
31. Aran D, Hellman A. (2013) DNA methylation of transcriptional enhancers and cancer
predisposition. Cell 154(1):11-3. doi: 10.1016/j.cell.2013.06.018.
32. Nagaoka M, Shiraishi Y, Sugiura Y. (2001) Selected base sequence outside the target binding
site of zinc finger protein Sp1. Nucleic Acids Res 29(24): 4920-9. doi:
10.1093/nar/29.24.4920.
33. Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, et l. (1994) Sp1
elements protect a CpG island from de novo methylation. Nature 371(6496): 435-8.
doi:10.1038/371435a0.

49

34. Schneider CA, Rasband WS, Eliceiri KW. (2012) NIH Image to ImageJ: 25 years of image
analysis. Nature methods 9(7): 671-675, doi:10.1038/nmeth.2089.
35. Lutsik P, Feuerbach L, Arand J, Lengauer T, Walter J, Bock C. (2011) BiQ Analyzer HT:
locus-specific analysis of DNA methylation by high-throughput bisulfite sequencing. Nuc
Acids Res web server issue. doi: 10.1093/nar/gkr312.

50

CHAPTER 3
ABERRANT DNA METHYLATION AT IMPRINTING CONTROL REGIONS
CORRELATES WITH AN INFILTRATIVE GROWTH PATTERN
3.1 Introduction
Imprinted genes are mainly expressed from a single allele based upon the allele’s parental
origin [1]. Thus far, there have been just over 100 imprinted genes identified by conventional
methodology; however, a far greater number of imprinted genes may exist due to recent data
obtained by implementing modern whole-transcriptome sequencing technologies [2,3].
Nevertheless, the well-known imprinted genes are clustered in discrete chromosomal domains,
which often contain a differentially methylated master cis-regulatory element termed an
Imprinting Control Region (ICR) [1,4,5]. ICRs are accompanied by other cis-regulatory elements
such as enhancers and differentially methylated promoters that act synergistically within their
respective imprinted domain to elegantly control imprinted gene dosage [1,6]. While DNA
methylation is transient among the other cis-regulatory elements depending on developmental
contexts and cell types, DNA methylation at ICRs is exceedingly stable [1,6,7]. The stability of
this epigenetic mark at ICRs is paramount due to their control over several imprinted genes
within a domain that have key roles in cell growth, division or death [8,9,10]. Consistent with
this, imprinted genes have gained much attention as both tumor suppressor genes and oncogenes
[11,12,13,14,15]. Indeed, epigenetic perturbations within imprinted domains have been reported
in a variety of both human and mouse malignant neoplasms [16,17]. However, the timing in
which epigenetic change occurs within imprinted domains, especially at ICRs, is still unclear.
DNA methylation is an important epigenetic regulator of gene expression. Misregulation of
DNA methylation in tumor cells is well recognized as an epigenetic alteration that results in
significant expression level differences of genes that contribute to the carcinogenic process
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[14,15,18,19,20,21]. The genome of any given normal cell by default is virtually stifled with
DNA methylation, with the exception of specific gene promoters and cis-regulatory elements
such as enhancers that contribute to the expression of genes necessary for the proper function of
the respective cell. However, during carcinogenesis, the levels of DNA methylation are
drastically reduced genome wide [22]. There are two distinct drastic reductions in 5methylcytosine that occur throughout the genome during the carcinogenic stages: first, during the
transition of normal cells to immortalized tumor cells, and second, as benign tumor cells acquire
infiltrative capacity [22]. Interestingly, hypermethylation at specific regulatory elements such as
tumor suppressor gene promoters occurs concomitantly with genome wide hypomethylation
during these critical transitional stages. Although ICRs have been well identified as targets for
hypermethylation, the functional role that this epigenetic aberration plays during the
carcinogenesis process remains largely uncharacterized [16,17]. Does hypermethylation at ICRs
contribute to the initiation of tumor formation, the proliferation of tumor cells, or the transition
of a benign process to that of an infiltrative one?
In the current study, we exploited the KrasG12D genomic mutation to initiate carcinogenesis
in mice and surveyed the epigenetic stability at ICRs in two fundamentally different neoplasms:
squamous papilloma that remains a benign process but exhibits continual growth, and T-cell
lymphoblastic lymphoma that rapidly acquires infiltrative capacity. This comparison allowed
further characterization of the functional role that aberrant DNA methylation at ICRs plays
during the carcinogenic process. According to the results, ICRs remain epigenetically stable
during the initiation of carcinogenesis and throughout the growth of tumors. However, DNA
hypermethylation was observed across virtually all ICRs in infiltrative tumor cell populations
regardless of their duration. These data suggest ICRs are targeted during the second phase of
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DNA methylation alterations to the genome and epigenetic instability among ICRs contributes to
the infiltrative capacity of tumor cells. Detailed results and the relevant discussion are presented
below.

3.2 Results
In this study, we sought to test whether the instability of DNA methylation at ICRs is
primarily associated with the transition of tumor cells to more infiltrative states. We also sought
to compare the relative stability of DNA methylation at ICRs with that of other regulatory
sequences such as Evolutionarily Conserved Regions (ECRs) that are known to be putative
enhancers and associated with the ICR of their respective imprinted domain. To accomplish this,
we utilized a floxed allele that contains the oncogenic KrasG12D mutation to initiate
tumorigenesis. The LSL-KrasG12D allele contains a Lox-Stop-Lox (LSL) transcriptional stop
cassette within the first intron, and a point mutation in the second exon that causes a substitution
(glycine to aspartic acid) at the 12th amino acid of the KRAS protein (Figure 3.1) [23,24]. Upon
the activity of cyclic recombinase (Cre), the stop cassette is removed from the 1st intron allowing
transcription to proceed and produce a full-length transcript that encodes the oncogenic
KRASG12D protein.
It has been previously reported that the KrasG12D mutation is sufficient to initiate both an
infiltrative T-cell neoplasm and benign squamous cell papilloma [16,25,26]. Here, we bred mice
that express Cre under the Mouse Mammary Tumor Virus long terminal repeat promoter
(MMTV-Cre) with the LSL-KrasG12D line to simultaneously target oncogenic KrasG12D to Tcells and epithelial cells (Figure 3.1) [27,28]. Using this breeding scheme, we obtained 80 mice
from 11 litters with an average litter size of about 7. Of the 80 total mice, 28 were positive for
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Figure 3.1. Targeting oncogenic KrasG12D to mouse T-cells and epithelial cells. (A) Structure
of the conditional LSL-KrasG12D allele. Once Cre removes the transcriptional stop cassette,
transcription of oncogenic KrasG12D proceeds. (B) Breeding scheme involving mouse lines
LSL-KrasG12D and MMTV-Cre. The numbers in parentheses indicate how many pups were born
in each litter, the red number indicates the average litter size, and the blue numbers indicate how
many mutant mice were obtained out of the expected number based on Mendelian inheritance.
(C) Gross image of a thymic T-cell lymphoma that is markedly expanding the anterior
mediastinum in a KrasG12D mouse. (D) Gross image of a squamous papilloma in and around the
mouth of a KrasG12D mouse. (E) Histological image of a thymic T-cell lymphoma in a
KrasG12D mouse with neoplastic lymphoid cells completely effacing the normal architecture of
the thymus and surrounding mediastinal soft tissue (200x magnification). (F) Histological image
of a squamous papilloma in a KrasG12D mouse showing the proliferated epithelium forming
multiple finger-like projections with maintenance of the tissue boundaries (100x magnification).
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the recombined KrasG12D allele, which deviated significantly from the expected Mendelian
ratio (P=0.007, chi-square). All of the recombinant progeny developed squamous papilloma
and nearly 40% developed thymic lymphoma as well as squamous papilloma (Figure 3.1) [16].
Unlike the thymic lymphoma, which infiltrated and extensively replaced the surrounding tissues
(Figure 3.1), the squamous papillomas were benign. The squamous papilloma lesions retained an
exophytic growth pattern with an overall thickening of the epithelial layer into fingerlike
projections (Figure 3.1). In sum, a mouse breeding scheme utilizing KrasG12D/MMTV-Cre mice
was successful in obtaining mice that developed both benign and infiltrative lesions.
DNA methylation at ICRs remained stable with the 50% methylation levels in benign tumor
cells, but became unstable with hypermethylation showing greater than 50% methylation levels
in infiltrative tumor cells (Figure 3.2). We sampled 15 squamous papilloma tumors and
measured the DNA methylation levels by COmbined Bisulfite Restriction Analysis COBRA at
11 ICRs, including Igf2r, Zac1, H19, Grb10, Ig, Nespas, Peg10, Peg3, Mest, Snrpn, and Rasgrf1
[16, 29, 30, 31]. The 15 tumors varied in age from 1 month to 4 months and thus size from small
to large. Nevertheless, DNA methylation at ICRs remained stable throughout the growth of all
the squamous papilloma tumors. This was apparent, as the ratio of digested bisulfite PCR
amplicons (representing methylated DNA) to undigested amplicons (representing unmethylated
DNA) in the tumors samples was not significantly different from the ratio of normal tissue
samples. We then compared these methylation data in squamous papilloma to that of thymic
lymphoid proliferative lesions histologically determined to be hyperplastic, atypical hyperplastic,
and neoplastic [16,32,33]. While DNA methylation at ICRs remained stable in hyperplastic and
atypical hyperplastic cells, it became unstable in infiltrative neoplastic cells (Figure 3.2). DNA
methylation significantly changed at 9 of the 11 ICRs tested, including H19, Grb10, Ig, Nespas,
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Figure 3.2. DNA methylation signatures at ICRs in benign squamous papilloma and infiltrative
thymic T-Cell lymphoma. (A) Representative DNA methylation data from 11 ICRs in squamous
papilloma and thymic lymphoid proliferative lesions generated by COBRA. Data from 7 out of
the 15 squamous papilloma tumors are shown and compared to a sample of normal skin denoted
with an N. Data from 1 normal thymus (N) and 3 representative thymic lymphoma samples are
shown: A – hyperplastic, B – atypical hyperplastic, and C – neoplastic. The red C denotes where
hypermethylation at ICRs occurred. Unmethylated DNA is denoted with a blue U, and
methylated DNA is denoted with a red M. (B) Summary of DNA methylation changes at the 11
ICRs in papilloma and thymoma. Red coloration represents significant hypermethylation based
on at least 2 of 15 samples having a P value less than 0.05.
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Peg10, Peg3, Mest, Snrpn, and Rasgrf1 (Figure 3.2). In sum, the stability of DNA methylation at
ICRs displayed a major difference between tumor cells of different states, benign versus
infiltrative.
Certain regulatory sequence elements within imprinted domains became epigenetically
unstable in the nonmalignant setting. We surveyed the DNA methylation status of various
regulatory sequence elements (ICRs, somatic differentially methylated regions (DMRs), ECRs,
and promoters) within three imprinted domains (Peg3, Grb10, and H19) to compare the
epigenetic stability of the ICRs to other sequence elements within their respective imprinted
domains (Figure 3.3). We found that there was no clear trend as to which type of sequence
element first experiences epigenetic change; rather, certain sequence elements experienced
significant changes in DNA methylation in the benign squamous papilloma lesions. Specifically,
the Zfp264 promoter of the Peg3 domain became significantly hypermethylated in 5 out of 15
tumors (Figure 3.4); whereas, the ICR and ECR18 of the Peg3 domain showed no significant
change in DNA methylation (Figure 3.3). On the contrary, the ECR1 of the H19/Igf2 domain
became significantly hypermethylated in 2 out of 15 tumors (Figure 3.4); whereas, none of the
other sequence elements in the domain showed significant change in DNA methylation (Figure
3.3). While certain sequence elements in both the Peg3 and H19/Igf2 domains experienced
significant changes in DNA methylation, all sequence elements in the Grb10 domain remains
stable in all squamous papilloma lesions (Figure 3.3). In sum, the DNA methylation at all four
elements tested, ICRs, DMRs, promoters and ECRs, behave similarly during carcinogenesis,
although some elements are affected earlier than others in individual cases.
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Figure 3.3. DNA methylation signatures of various sequence elements within imprinted domains
in squamous papilloma and thymoma. (A) Peg3 domain structure. Sequence elements analyzed
include Zim2 – Differentially Methylated Region (DMR), Zim1 promoter, APeg3 promoter, Peg3
– Imprinting Control Region (ICR), ECR18, and Zim3/Zfp264 – DMR. (B) Grb10 domain
structure. Sequence elements analyzed include Ddc – promoter, ECR154, Grb10 – ICR, Grb10
promoter, and Cob1 promoter. (C) H19/Igf2 domain structure. Sequence elements analyzed
include ECR2, H19 promoter, H19 – ICR, ECR1, and Igf2 – DMR. All sequence elements are
listed in order as they appear in the figure from left to right.
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Figure 3.4. Representative COBRA data from the H19 – ECR1 and the Zfp264 – promoter.
Squamous papilloma samples are numbered 1-15 and compared to a sample of normal skin (N).
The numbers underneath the gel images indicate percent methylation for each sample. Red
numbers indicate the samples that showed significant DNA methylation change based on P
values less than 0.05. Unmethylated DNA is denoted with a blue U and methylated DNA is
denoted by a red M.

3.3 Discussion
Many efforts have been focused on determining the potential role that imprinted genes may
play during carcinogenesis [11,12,16,17,22,34,35,36]. Analyses of human malignant neoplasms
have revealed that many ICRs and putative enhancers within imprinted domains show significant
epigenetic change pertaining to DNA methylation, and that these changes often correlate with the
expression level differences of nearby imprinted genes within the domain [17]. However, the
question whether this epigenetic instability within imprinted domains contributes to the
infiltration potential of tumor cells remains elusive [16]. In the current study, we initiated
tumorigenesis in mice with the KrasG12D mutation, and subsequently compared the epigenetic
stability of various regulatory sequence elements within imprinted domains between two
fundamentally different neoplasms, benign squamous papilloma and malignant T-cell
lymphoma. We show that there is a stark contrast in the epigenetic stability at ICRs between the
benign and infiltrative lesions studied: while DNA methylation among ICRs was stable in the
benign lesions, including in the thymic lymphoid hyperplastic lesions, it was highly unstable in
the infiltrative lesions. Furthermore, we show that DNA methylation is unstable at certain
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regulatory sequence elements specific to their imprinted domain in both the benign and
malignant lesions. Overall, it appears that imprinted domains are most vulnerable to epigenetic
change in infiltrative tumor cells.
DNA methylation settings at ICRs are critical for maintaining parent-of-origin specific
expression of many genes within an imprinted domain [7]. ICRs contain various sequence
elements that commonly manifest aberrant DNA methylation trends in tumor cells [19]; thus, the
stability of DNA methylation at ICRs is concerning in the context of carcinogenesis. Moreover,
ICRs are susceptible to the Knudson two-hit hypothesis because one allele is already methylated
and silenced in the native state. Therefore, ICRs can potentially respond to either
hypomethylation events or hypermethylation events. Indeed, the Knudson two-hit hypothesis has
been well supported with hypermethylation of imprinted genes in malignant tumors [14,16,17].
However, the timing when ICRs manifest epigenetic change, particularly DNA methylation
changes, is debatable. First, do epigenetic changes at ICRs coincide with the initiation of
carcinogenesis or, second, do epigenetic changes at ICRs coincide with neoplastic transformation
of tumor cells?
According to the results of our analyses of the squamous papillomas, DNA methylation at
ICRs remained stable throughout the duration of these benign tumors (Figure 3.2). This suggests
that, epigenetic instability at ICRs is not associated with the early events of carcinogenesis.
However, this epigenetic stability is particularly intriguing given that two genome-wide DNA
demethylation events take place in mouse skin carcinogenesis: first, during transition from
immortalized non-tumorigenic keratinocytes to benign papilloma cells and, second, during
transition from epithelial to spindle cells, which is associated with a sharp increase in infiltrative
potential (Figure 3.5) [22]. Moreover, these genome-wide reductions in 5-methylcytosine are
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Figure 3.5. DNA methylation trends during carcinogenesis. (A) Depicts the genome wide
reductions in 5-methylcytosine during the transition of normal cells to benign tumor cells (first
hash mark) and when benign cells gain infiltrative potential (second hash mark). (B) Depicts
specific hypermethylation events that coincide with the genome wide hypomethylation trends.
Red line represents hypermethylation at Tumor Suppressor Gene (TSG) promoters and the blue
line represents hypermethylation at Imprinting Control Regions (ICRs).
accompanied by two waves of DNA hypermethylation at specific tumor suppressor gene
promoters [22]. Unfortunately, we were unable to analyze the epigenetic activity at ICRs during
the second wave of DNA methylation changes in the squamous papilloma panel as these
epithelial cells did not undergo the epithelial-mesenchymal transition. Furthermore, these
squamous tumors did not even advance to squamous cell carcinomas. Nevertheless, the
epigenetic stability at ICRs throughout the first reconstruction of the epigenome suggests
imprinted genes do not have a role in the initiation of carcinogenesis.
Epigenetic stability at ICRs is challenged during the second reconstruction of the DNA
methylome (Figure 3.5). This wave of DNA methylation changes is associated with increase in
the infiltrative potential of tumor cells. This is demonstrated by the results from the T-cell
lymphoblastic lymphoma panel (Figure 3.2). In addition to neoplastic thymic lymphoid lesions,
this panel also included hyperplastic and preneoplastic thymic lymphoid lesions [16]. ICRs
remained epigenetically stable in the hyperplastic and preneoplastic specimens regardless of the
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duration of the lesions. In contrast, malignant neoplastic specimens displayed marked epigenetic
instability with nearly all the ICRs becoming hypermethylated, regardless of the duration of the
lesion. ICRs acquiring hypermethylation does not necessarily confer repression of imprinted
genes as seen with hypermethylation in tumor suppressor gene promoters [35]. For instance,
hypermethylation at the ICR of the H19/Igf2 domain can potentially result in complete
repression of H19 and bi-allelic expression of Igf2, a known oncogene, whereas
hypermethylation at the ICR of the Peg3 domain can potentially result in repression of Peg3, a
putative tumor suppressor [5]. Thus, concomitant hits to multiple ICRs can simultaneously
activate oncogenes while suppressing tumor suppressor genes. Overall, it appears ICRs are
targeted to be hypermethylated in the midst of the second drastic genome wide reduction in 5methylcytosine, a hallmark of tumor progression to malignant disease. This raises the notion that
epigenetic instability among ICRs could enhance the infiltrative capacity of tumor cells.
The epigenetic stability among the ICRs in the benign tumors is not a common theme among
other regulatory sequences within their respective imprinted domain. This is demonstrated by our
analysis of the H19/Igf2 and Peg3 imprinted domains (Figure 3.3). For instance, the Zfp264
promoter within the Peg3 imprinted domain became hypermethylated in several benign
specimens while the ICR retained normal DNA methylation patterns. This observation
demonstrates the specificity of DNA methylation changes among sequence elements within
imprinted domains during tumor progression. The observed specificity of DNA methylation
changes within a single imprinted domain further supports the notion that epigenetic changes at
ICRs could potentially be involved in enhancing the infiltrative potential of tumor cells as ICRs
are only targeted during the second reconstruction of the DNA methylome.
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To our knowledge, this is the first study to compare the epigenetic stability among ICRs
between benign and malignant tumor cells driven by the same genomic mutation, KrasG12D.
The results from the DNA methylation analyses of this study demonstrate that ICRs remain
stable during the first reconstruction of the DNA methylation landscape but are targeted
specifically by DNA hypermethylation during the second reconstruction of the DNA methylation
landscape - a hallmark that defines the transition of benign tumor cells to malignant. Further
investigation is required to determine whether the observed changes in DNA methylation at ICRs
directly enhance the infiltrative potential of tumor cells. However, considering the effects that
aberrant DNA methylation at an ICR can have on an entire imprinted domain, it is likely that
concomitant hits to several ICRs can result in an aberrant protein environment within a tumor
cell whereby several tumor suppressors are shut down and several oncogenes are activated.
These dynamic changes in critical imprinted gene products may very well enhance a tumor cell’s
ability to infiltrate tissue boundaries. Lastly, monitoring DNA methylation at ICRs may be a
useful diagnostic in the clinical setting in determining the progression of a neoplasm.

3.4 Materials and methods
Two mouse strains were purchased from Jackson laboratories: B6.129-Krastm4Tyj/Nci
(LSL- KrasG12D) and STOCK Tg(MMTV-Cre)4Mam/J (MMTV-Cre) [23,24,37,38]. The LSLKrasG12D mice were maintained as heterozygotes and bred with homozygous MMTV-Cre mice.
Mice weaned at 21 days post partum were separated by sex and marked by a hole punch with
varying positions in the left ear. Ear clips were taken from the right ear for genomic DNA
isolation and subsequent PCR analysis. Sample preparation and PCR protocols have been
previously described [16]. Primer sets for genotyping can be found in Table 2.1.
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Mice were monitored daily for signs of distress or weight loss equaling 15% of total body
weight, and sacrificed according to the guidelines set forth in the IACUC protocol #16-060.
Upon euthanasia, mice were submitted to full necropsy. Samples of squamous papilloma and
thymic lesions were placed directly in tail lysis buffer with Proteinase K for subsequent DNA
isolation. Detailed buffer compositions and DNA extraction protocols were previously reported
[16]. The remaining portion of these lesions and representative samples of all other tissues were
fixed for at least 48 hours in 10% neutral buffered formalin (Thermo Scientific, Cat. # 5725) and
then transferred to 70% ethanol. Tissues were further processed according to standard protocols
for hematoxylin and eosin (H&E) staining and examined by a board certified pathologist (IML).
Combined Bisulfite Restriction Analysis (COBRA) was performed for DNA methylation
analyses [29]. A detailed description of the protocol and reagents used for this study has been
previously reported [16]. Table 2.1 contains detailed information pertaining to the genomic
locations analyzed and their respective oligonucleotide bisulfite primer sets. Three independent
technical replicates were performed for each sample and each primer set. DNA methylation
percentages were calculated and statistically analyzed as previously described [16]. For the
squamous papilloma panel, 28 samples were analyzed initially; however, only 15 samples were
used for statistical comparisons based on the consistent successful bisulfite PCRs across all
primer sets.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
The distribution of DNA methylation is reshaped during the onset of cancer [1]. The
reshaping of DNA methylation at ICRs can have profound impacts on gene regulation
throughout imprinted domains [2]. Imprinted domains contain many genes that have oncogenic
and tumor suppression potential whose parent-of-origin mono-allelic gene expression is
regulated by DNA methylation at ICRs [3,4]. Therefore, improper maintenance of DNA
methylation settings at ICRs can significantly contribute to carcinogenesis by either allowing biallelic expression of proto-oncogenes or completely silencing expression of tumor suppressor
genes. While DNA methylation changes within imprinted domains have been serendipitously
detected in human cancer, the DNA methylation changes throughout imprinted domains has not
been exhaustively characterized during carcinogenesis [5].
This study provides the first report of the epigenetic stability at all of the various types of
regulatory sequence elements within imprinted domains during the development of murine
invasive T-cell lymphoma and benign squamous papilloma both of which were driven by the
KrasG12D oncogenic mutation. By contrasting the epigenetic response of imprinted domains
during the development of two fundamentally different tumors (i.e., infiltrative versus benign),
this study was able to demonstrate that epigenetic instability within imprinted domains correlates
with the transformation activity of tumor cells from benign to infiltrative. Furthermore, ICRs
were identified as the main sequence element targeted for DNA methylation changes within
imprinted domains during this transition of tumor cells. However, enhancer regions also showed
a similar amount of DNA methylation activity, more rigorous analysis of enhancer elements is
needed. Also, it is still unclear whether enhancer elements within imprinted domains are unique
or if enhancer elements throughout the genome respond similarly during carcinogenesis. Overall,

68

DNA methylation at ICRs and enhancer elements within imprinted domains show high levels of
plasticity during carcinogenesis; however, significant DNA methylation changes at enhancer
elements may be more readily detected than at ICRs due to the normal methylation levels at
ICRs being already at fifty percent.
Cancer cases exponentially increase with the accumulation of mutations within cells[6]. Cells
can tolerate a fare amount of mutation via tumor suppression mechanisms such as cell
senescence, apoptosis, autophagy and DNA damage repair; however, disruption of one or more
of these mechanisms can conspire with other progressive events such as epigenetic alterations to
accelerate cell transformation towards malignancy [6]. DNA methylation changes are hallmarks
of these cell transformations [7,8]. First, overall levels of 5mC are drastically reduced during
transformation of normal cells to benign tumor cells and again when benign tumor cells
transform to malignant cells [7]. Second, focal DNA hypermethylation at CpG islands housing
promoters of tumor suppressor genes are also observed during each of these transformations.
Thus, it can be inferred that a given gene is relevant to a specific transformation event during
carcinogenesis based upon the timing of DNA methylation changes at its promoter. In the case of
imprinted genes, it appears that they may promote the transformation of benign cells to
malignant cells due to the bulk of DNA methylation changes within imprinted domains occurring
at this time. This role during carcinogenesis fits with the function of many imprinted genes, as
they are commonly involved with cellular processes such as apoptosis, cell cycle, angiogenesis,
and metabolism [3,9,10,11]. Overall, this study highlights that DNA methylation changes at
ICRs occur when benign tumor cells transform to infiltrative tumor cells.
Although DNA methylation is a well-recognized molecular change in cancer, the signals that
drive these molecular changes during carcinogenesis are largely unknown. The signals that
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dictate gene expression and DNA methylation patterns during normal development may also
choreograph the resetting of DNA methylation patterns in tumor cells. For instance, as seen
within imprinted domains, transcription originating from an upstream promoter may signal for
downstream CpG islands to become methylated [12]. Hypomethylation of intergenic regions
may lead to the activitation of cryptic transcription originating from the upstream promoters;
thus, providing a link between widespread hypomethylation and focal hypermethylation of CpG
isalnds. Efforts thus far have identified several key players involved in carrying out the process
of DNA methylation, which is a significant and big step toward uncovering what is ultimately
responsible for generating the order. It will be exciting to see what future efforts will identify as
underlying commands that dictate DNA methylation resetting.
DNA methylation may be targeted for therapeutic interventions [13,14]. For instance,
inhibiting DNA methylation in tumor cells with DNA-demethylating agents has been successful
as a therapeutic intervention. While increasing the loss of DNA methylation in tumor cells seems
counterintuitive as it increases chromosomal instability and can lead to abnormal expression of
genes that have oncogenic potential, it also appears that reversing the hypermethylation of house
keeping gene promoters significantly inhibits the transforming activity of tumor cells. Currently,
two compounds that inhibit DNA methylation have been approved for use in treating
myelodyplastic syndrome [15]. Briefly, both 5-azacytidine and 5-aza- 2-deoxycytidine bind to
DNMTs and inhibit their activity, and thus cause genome wide hypomethylation. While this
strategy has proven to be effective in reversing promoter hypermethylation, the non-specific
demethylation caused by these compounds can also create problems as mentioned above. The
advent of the clustered regularly interspaced short palindromic repeats/ CRISPR associated
protein 9 (CRISPR/Cas9) system has provided researches with a way to potentially address the
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pitfalls of the demethylating drugs by enabling targeted DNA methylation therapy to specific
loci [16]. By fusing either DNMTs or TETs to a deactivated Cas9 protein, DNA methylation can
either be written or erased at a target of interest. This system is still in its infancy however, and
as with any new therapeutic modality, delivery is a major hurtle. Furthermore, recent reports
have noted that this system does not work equally at different loci [17]. Nonetheless, the future
of targeting DNA methylation for cancer therapy is bright, and it will also provide us with a
method to better understand the dynamics of DNA methylation changes and how these changes
contribute to carcinogenesis.
Recently, it has been reported that the activity of transcription through CpG islands signals
DNMTs to deposit DNA methylation [12]. This mechanism can potentially be exploited for
targeting DNA hypermethylation to the promoter of an active gene housing an oncogenic
mutation thereby silencing the expression of the mutation driving carcinogenesis. In theory, by
activating transcription from an upstream promoter, RNA polymerase would then traverse the
downstream CpG island housing the promoter driving expression of the oncogenic mutation.
This transcriptional activity would then signal for the DNMTs to methylate the CpG island
thereby inactivating the promoter of the oncogene. The CRISPR/Cas9 system could be used to
deliver an engineered protein to the upstream promote and activate transcription. As a proof of
concept, a similar approach was developed by the Segal lab to treat Angel syndrome [18]. In this
case, a zinc finger protein was engineered to silence transcription of the Snrpn lncRNA thereby
relieving genomic imprinting of the silenced Ube3a allele. This allowed a non-mutated form of
Ube3a to be expressed and rescue the effects that the loss-of-function mutation on the nonimprinted allele was causing. Advances in our ability to manipulate both genetic and now
epigenetic information can be used to exploit mechanisms that regulate gene expression for not
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only gaining a better understanding of normal cellular processes but also to treat human disorders
and diseases.
By characterizing the epigenetic response of imprinted domains during carcinogenesis, this
study provides the community with valuable results that can help guide future research that aims
to edit the aberrant DNA methylation within imprinted domains. Furthermore, clinicians can use
these data as potential biomarkers during the prognosis of T-cell lymphoma progression.
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APPENDIX A: TABLE OF GENOMIC LOCI AND PRIMERS
Imprinted genes
Gene
Nespas

Primer Name
mNespas_ICR_bis_F
mNespas_ICR_bis_R
mNespas_ICR_bis_c
mGnas_DMR_bis_c
mGnas_DMR_bis_d
mGnas_PRO_bis_a
mGnas_PRO_bis_b

5'- Primer sequence -3'
GGGTGTGAGAGGTTTGGAGAGTTTATAAGA
CCAACTAAATCTCAACCACTAACCCACTCC
GTTTATGGGGGTTTTTGATTTTTTTATTTT
GAGTTTTTTGAATTTGAGTTTGATTA
CTCTCAAACTCCTAAATAATAAACT
TAAGAAGATGGAGAAGAAGTTGTTGGAGTA
CATCATCTTCTTCATCAATATCACTATCCCA

Genomic position
PRR product length
Chr2: 174294993-174295604
F/R: 611 bp; c/R: 328
bp
(use c/R for
sequencing)
Chr2: 174284913-174285242
328 bp

Enzymes used for COBRA
Loci within imprinting domain
Taq1, Hph1, Mbo1
Nespas, Gnas

Chr2: 174328782-174329063
281 bp

Bbs1

Peg10

mPeg10_ICR_bis_a
mPeg10_ICR_bis_b

GTAAAGTGATTGGTTTTGTATTTTTAAGTG
TTAATTACTCTCCTACAACTTTCCAAATT

Chr6: 4747895-4748446

551 bp (sequencing did Hha1, Hph1
not work)

Sgce, Asb4, Dlx5, Calcr, Peg10, Ppp1r9a, Pon2, Pon3,
Tfpi2, Casd1

Peg3

mPeg3_ICR_bis_15.2
mPeg3_ICR_bis_16.1
mPeg3_PRO_bis_11
mPeg3_PRO_bis_12
mPeg3_ECR18_bis_a
mPeg3_ECR18_bis_b

TAGGTAGTTAATTAGGATAAGTTTGTGTAG
CCTATTACAAAACCACCACAATAAACATCA
AGAGGGTGTATGTTGTAGAGTAGTTAGGTG
CATCCCTTCACACCCACATCCCATCC
GGGGTTTTTTAGAATTTGTTTTATGGAGGT
CTCTATCTCTTTAAATATATCCAAAACTATC

Chr7: 6729538-6729883

345 bp

Taq1, Hph1

Peg3, Zim1, Usp29, Zim3, Zfp264, Zim2

Chr7: 6730213-6730667

454 bp

Hpa1

Chr7: 6913709-6914130

421 bp

Taq1

Snrpn

mSnrpn_ICR_bis_1
mSnrpn_ICR_bis_4
mSnrpn_ICR_bis_IF

TATGTAATATGATATAGTTTAGAAATTAG
AATAAACCCAAATCTAAAATATTTTAATC
AATTTGTGTGATGTTTGTAATTATTTGG

Chr7: 60004987-60005420 420 bp

Bstu1, Hha1

Snrpn, Mkrn3, Mkrn3os, Ipw, Ube3a, Ndn, Snurf, Mag
el2, Snord116, Snord64, Snord115, Peg12, Atp10a

H19

mH19_ICR_bis_BF3
mH19_ICR_bis_BR3
mH19_ECR1_bi_a
mH19_ECR1_bis_b
mH19_ECR2_bis_a
mH19_ECR2_bis_b

ATAGATGGTGATAGGGGAGAAAATTTA
AAATTCTACAAAAAAACCATACCCTATTCTT
TTAGGTTTGAGGTGGTAGTTTTTAG
TAAACTTTCCCAAAAAAACTAAACC
GGGGATTTTTTTTTTGTATTTATAGTTG
ACTAAAAAAAAACCTACTCTCCCTCAAACTC

Chr7: 142581719-142582121
307 bp

Cla1

Chr7: 142,611,866-142,612,222
356 bp

Taq1

Ins2, H19, Igf2, Ascl2, Cdkn1c, Phlda2, Kcnq1, Igf2os,
Cd81, Tssc4,
Osbpl5, AF313042, Nap1l4, Th, Tspan32,Slc22a18,
Tnfrsf23, Dhcr7, Kcnq1ot1

Chr7: 142,571,477-142,571,823
346 BP

BSTU1

Igf2

mIgf2_DMR1_bis_a
mIgf2_DMR1_bis_b

GTTATATTTTGATTAAATAAGGTTAGGTGAAGG
CACCTCTAATCCTTATAAAACCAAATTAAACTAC

Chr7: 142665283-142665695
413 bp

Hinf1

Grb10

mGrb10_PRO_bis_a
mGrb10_PRO_bis_b
mGrb10_ICR_bis_c
mGrb10_ICR_bis_d
mGrb10_E154_bis_F
mGrb10_E154_bis_R

GGAGAGGTAATTAGTAAAGGTAGAGAG
ATACCAACACTCCCAAATCCCAAAC
GTTGTTTATTATTTGGTTGAGAGTAGA
TAATCCAAATAATAAACAACTCCTAC
TTAGAGTTGTTTGGGATAAAGGAGAGTA
TCTAAAACCCAATAACAATAACCTAACCAC

Chr11:12036436-12036697262 bp

HpyCHIV

Chr11:1202541912025726
chr11:11,856,74511,857,746

307 bp

Hha1, Hph1

304 bp

Taq1

Cob1

mCobl_pro_bis_F1
mCobl_pro_bis_R1

GGTGGGTATYGAGTTATTTGTTTAGT
AATATCCACACTCCAACCTCACTACT

chr11:1236453812365200

335 bp

Bstu1, Taq1

Ddc

mDdc_pro_bis_F1
mDdc_pro_bis_R1

ATGTTATTTTGTTGYGTATGGTTTTGTGA
TAGGTTTATTTTGTTGTYGGGATTGTTTAG

chr11:11797984-11798367 381 bp

Taq1, HpyCHIV

Zac1/Plagl1

mZac1_ICR_bis_a
mZac1_ICR_bis_b

GAGTTTTTTGAATTTGAGTTTGATTA
ATCCCAACCCAAACTAAATAACAAATC

Chr10:13090541-13090791250 bp

Taq1, Bstu1, HpyCHIV

Ig

mIg_ICR_bis_C.1
mIg_ICR_bis_D.1
mDlk1_DMR_bis_c
mDlk1_DMR_bis_d
mDlk1_PRO_bis_F
mDlk1_PRO_bis_R
mGtl2_DMR_bis_a
mGtl2_DMR_bis_b

AAGTTTATGGTTTATTGTATATAATGTTGT
CATCCCCTATACTCAAAACATTCTCCATTA
TGTGTTTTGGTTTGAGAGATTAAGTAAGAG
CTCACCTAAATATACTAAAAACAAATACC
GTGTTTTAGGGATAGGTAGTAAGGTTTGTT
ACCACACTCTTTAACTAAACCAATACCTAC
ATTATGTTTAATTGGATTTATTAATGGTG
CTAATCTAACAAACCAAAAACCATTTACAC

Chr12:109528222-109528567
345 bp

Chr12: 109452874-109453320
446 BP

Bstu1, Mlu1, Mbo1, HpyCHIV
Dlk1, Ig,Meg3/Gtl2, Rtl1, AF357428, AF357341, Dio3,
Mir376b, Mir154, Mir337, Mir433, Mir411, Mir127, Mir3
80,Mir370,
Mbo1, Hpy991, Fok1
Mir136, AF357426, Mir134, Mir410, AF357425, Mir434,
Mir431, Rian, Begain
Hpy1881, Hha1

Chr12: 109542677-109543088
411 bp

Bstu1, Hph1

Igf2r

mIgf2r_ICR_bis_a
mIgf2r_ICR_bis_b

TATTTTGGGGAATTGAGGTAAGTTAGGGTT
ATTTTCTTATAACCCAAAAATCTTCACCCT

Chr17:12741407-12741688281 bp

Mlu1

Slc22a3, Slc22a2, Airn, Igf2r, Pde10a

Rassgrf1

mRassfrf1_ICR_bis_FK
mRassfrf1_ICR_bis_RK

GGAATTTTGGGGATTTTTTAGAGAGTTTATAAAGT Chr9: 89,879,621-89,880,021
400 bp
CAAAAACAACAATAATAACAAAAACAAAAACAATAT

Bstu1

Rasgrf1, Mir184

Mest

mPeg1/Mest_bis_OF
mPeg1/Mest_bis_OR

GATTTGGGATATAAAAGGTTAATGAG
TCATTAAAAACACAAACCTCCTTTAC

Chr6: 30,736,677-30,737,367
690 bp

Mbo1, Taq1

Copg2, Copg2os2, Nap1l5, Klf14, Mest, Copg2os1, Mir335

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

Gatm, Sfmbt2
Nnat, Blcap

GGAGTTAAGTTTAAGTGGAATAGAATGTG
AACTATTCAAAAGTAGCCACAATGACACCT

Chr14: 9550402-11162035 285 bp

Taq1

Gnas

Dlk1

Gtl2

Tumor suppressor genes
mFhit_PRO_bis_c
Fhit
mFhit_PRO_bis_b

Chr12:109459472-109459897
425 bp

N/A
N/A

Taq1, Bstu1, Fok1

Mgmt

mMgmt_PRO_bis _F
mMgmt_PRO_bis_d

GGTTTGGAAGAAGAGGTTTGTTTTAGGAAT
TCACCAACTTACAAACTACAAACAACAAC

Chr7: 136894337-136894691
354 bp

MluI

Apc

mApc_PRO_bis_F
mApc_PRO_bis_R

GAAAGGTGAGTAGGTTAGAGATTTAGGATT
CTAAAAAAACCACTCCTCACTCCACCTTCC

Chr18: 34220741-34221103362 bp

FokI

Gstp1

mGstp1_PRO_bis_F
mGstp1_PRO_bis_R

TTTAGTATAAAGTGGAAGGGAGTTGGATAT
CAGAGTGGTACACTTTCCCACCCCATCTCC

Chr: 19: 4035411-4037912 469 bp

HhaI

Mlh1

mMlh1_PRO_bis_F
mMlh1_PRO_bis_R

CTCAGCTCTCAGAAATGAGCCAATAGGAAG
TGTGCATAATGGGAAACCAGCCTGGCAC

Chr9: 111228228-111271608
542 bp

FokI

Msh2

mMsh2_PRO_bis_F
mMsh2_PRO_bis_R

GTTTTTGGAAGGTTTGTAAGGTTGTAGAAG
CTCCACACCAACACCACTAAAACACAAAAC

Chr17: 87672330-87723713257 bp

Hpy99I

Rassf1a

mRassf1a_PRO_bis_F
mRassf1a_PRO_bis_R

GGGGTTTTTTGAAAGGGTTTATTTTTGTGT
GATCATCACAACTGACCAGCCCTCCACTGC

Chr9: 107551555-107562263
561 bp

Hpy99I

Chek2

mChek2_bis_F
mChek2_bis_d

TAAAAGTTTTTTTTTTAGGAATTTTGTTAG
AATACAAACTCCACCCTCAACCAATCAA

Chr14: 100815494-100815707
213 bp

Hpy99I

Kras F1
Kras Fcass
Kras R1

GTCTTTCCCCAGCACAGTGC
AGCTAGCCACCATGGCTTGAGTAAGTCTGCA
CTCTTGCCTACGCCAC CAGCTC

MMTV-Cre F
MMTV-Cre R

CTGATCT GAGCTCTGAGTG
CATCACTCGTTGCATCGACC

Genotyping
Kras

MMTV-Cre
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Ddc, Grb10, Cobl, Zrsr1, Commd1

Zac1/Plagl1
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